{"gene":"NFATC1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2002,"finding":"RANKL selectively induces NFATc1 expression via TRAF6 and c-Fos signaling pathways, evokes Ca2+ oscillations leading to calcineurin-mediated NFATc1 activation, and triggers a sustained NFATc1-dependent transcriptional program during osteoclast differentiation. NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts in response to RANKL, and ectopic NFATc1 expression causes precursor cells to differentiate without RANKL, establishing NFATc1 as a master transcriptional switch downstream of RANKL for terminal osteoclast differentiation.","method":"NFATc1-deficient ES cell differentiation assay, ectopic NFATc1 expression, Ca2+ oscillation imaging, genetic epistasis (TRAF6/c-Fos pathways)","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (loss-of-function ES cells, gain-of-function ectopic expression, Ca2+ imaging, pathway genetics), widely replicated across many subsequent studies","pmids":["12479813"],"is_preprint":false},{"year":1997,"finding":"Glycogen synthase kinase-3 (GSK-3) is a component of the NF-ATc kinase that phosphorylates conserved serines in the NF-ATc N-terminus, promotes nuclear export, and thereby opposes Ca2+-calcineurin signaling that drives nuclear import.","method":"Biochemical purification of NF-AT kinase, in vitro phosphorylation assay, nuclear localization assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — kinase purification plus in vitro phosphorylation assay, widely replicated and foundational finding","pmids":["9072970"],"is_preprint":false},{"year":2000,"finding":"GSK-3 phosphorylation of the conserved Ser-Pro repeat motifs in NFATc negatively regulates its intrinsic DNA binding activity, in addition to controlling its subcellular localization; calcineurin-mediated dephosphorylation enhances DNA binding.","method":"Gel mobility shift assay, in vitro phosphorylation, NFATc mutant analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation combined with mutant analysis and EMSA, single lab but multiple orthogonal methods","pmids":["11063740"],"is_preprint":false},{"year":2000,"finding":"JNK, ERK, p38, and CK2 physically associate with the NFATc N-terminal regulatory domain and directly phosphorylate Ser172 and conserved Ser-Pro repeats, blocking ionomycin-induced nuclear translocation; CK2 additionally phosphorylates a conserved motif downstream of the Ser-Pro repeats important for nuclear export.","method":"Co-immunoprecipitation, in vitro kinase assay, overexpression/inhibitor studies, subcellular localization assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct in vitro phosphorylation combined with Co-IP and functional localization assays, single lab with multiple orthogonal methods","pmids":["10652349"],"is_preprint":false},{"year":1997,"finding":"The DNA-binding domain (DBD) of NFATc has an unusual Rel-like fold that is both necessary and sufficient for DNA binding and cooperative transcriptional activation; despite overall structural homology to NF-κB p50, the two proteins use significantly different strategies for DNA recognition. A model was proposed for cooperative complex formation with AP-1 on the IL-2 enhancer.","method":"NMR solution structure determination, DNA binding assays, transcriptional activation assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure with functional validation of DNA binding domain boundaries, foundational structural study","pmids":["8990122"],"is_preprint":false},{"year":2001,"finding":"NFATc1 (NFATc) undergoes activity-dependent nuclear translocation in adult skeletal muscle fibers: slow-twitch electrical stimulation patterns (10 Hz continuous or 5-s trains) drive cyclosporin A-sensitive nuclear accumulation of NFATc-GFP foci, whereas fast-twitch patterns (50 Hz) or low-frequency (1 Hz) stimulation do not, indicating NFATc1 nuclear import contributes to slow fiber-type gene regulation.","method":"Live-cell GFP imaging in adult muscle fibers, electrical stimulation, pharmacological inhibition (cyclosporin A), kinase inhibitors","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct live-cell localization imaging with multiple stimulation conditions and pharmacological validation, single lab but rigorous controls","pmids":["11581284"],"is_preprint":false},{"year":2008,"finding":"NFATc1 is preferentially expressed by hair follicle stem cells in their niche downstream of BMP signaling, where it transcriptionally represses CDK4 to maintain stem cell quiescence; pharmacological or genetic ablation of calcineurin/NFATc1 signaling causes premature stem cell activation and precocious follicular growth.","method":"Conditional and complete NFATc1 gene ablation, pharmacological calcineurin inhibition, reporter/ChIP assays for CDK4 repression","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with specific phenotypic readout, gene target (CDK4) identified, replicated across pharmacological and genetic approaches","pmids":["18243104"],"is_preprint":false},{"year":2008,"finding":"NFATc1 binds a novel regulatory element at the pdcd1 (PD-1) locus and is required for PD-1 gene transcription upon T cell stimulation; mutation of the NFATc1 binding site abolishes promoter activity.","method":"Chromatin immunoprecipitation, reporter gene assay with binding site mutagenesis, calcineurin inhibitor and NFAT-specific inhibitor treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus mutagenesis of binding site plus reporter assay, multiple complementary methods in single lab","pmids":["18802087"],"is_preprint":false},{"year":1999,"finding":"NFATc1 isoforms B and C contain long C-terminal extensions beyond the previously described isoform A; isoform C possesses a second transactivation domain (TAD-B) in its C-terminal peptide that responds to T cell stimuli similarly to TAD-A but remains unphosphorylated, while isoform B exerts suppressive transcriptional effects through its shorter C-terminal peptide.","method":"Alternative splicing analysis, transactivation domain mapping, reporter assays, phosphorylation analysis in stimulated T cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional domain mapping with reporter assays and phosphorylation analysis, single lab","pmids":["10358178"],"is_preprint":false},{"year":2002,"finding":"NFATc1 and NFATc2 are both positive regulators of IL-4 gene transcription with intrinsically similar DNA-binding and transcriptional activities at the IL-4 gene, suggesting that the disparate IL-4 phenotypes in NFAT1−/− vs. NFAT2−/− T cells arise from differential regulation of the two proteins rather than intrinsic differences in their transcriptional activities.","method":"Constitutively active NFATc mutants (alanine substitutions), IL-4 transcription assays in T cells","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — constitutively active mutant approach with direct transcriptional readout, single lab","pmids":["12355451"],"is_preprint":false},{"year":2014,"finding":"NFAT2 (NFATc1) is required in follicular regulatory T cells (TFR) to upregulate CXCR5 expression, enabling their homing to B cell follicles; T cell-specific NFAT2 ablation reduces TFR cells in follicular populations and exacerbates lupus-like autoimmune disease.","method":"T cell-specific Nfat2 conditional knockout mice, immunization experiments, flow cytometry, disease scoring","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with TFR-intrinsic rescue experiments and mechanistic link to CXCR5 upregulation, multiple phenotypic readouts","pmids":["24590764"],"is_preprint":false},{"year":2003,"finding":"NFATc1 is required cell-intrinsically for normal B-1a cell development; NFATc1-deficient mice lack peritoneal and splenic B-1a cells, while NFATc2-deficient mice have a normal B-1a compartment; NFATc1 protein is elevated ~5-fold in B-1a versus B-2 cells.","method":"NFATc1-deficient and NFATc2-deficient mouse analysis, mixed-allotype chimeras, retroviral gene transduction, flow cytometry","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation plus cell-intrinsic rescue by retroviral transduction, multiple complementary approaches","pmids":["14595020"],"is_preprint":false},{"year":2006,"finding":"The calcineurin-NFATc pathway directly regulates AQP2 (aquaporin-2) expression in renal collecting duct cells through functional NFAT binding sites in the AQP2 proximal promoter; hypertonicity promotes nuclear translocation of NFATc proteins (in addition to TonEBP/NFAT5) to induce AQP2, and calcineurin activity is involved in TonEBP/NFAT5 induction by hypertonicity.","method":"Promoter mutational analysis, chromatin immunoprecipitation, nuclear translocation assays, calcineurin inhibitor studies","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus promoter mutagenesis plus nuclear translocation assays, multiple orthogonal methods in single study","pmids":["17166937"],"is_preprint":false},{"year":2011,"finding":"NFATC1 is expressed in epicardium-derived cells and is required for their invasion into myocardium; RANKL/calcineurin signaling activates NFATC1 to induce cathepsin K (CTSK) expression, enabling ECM degradation and cell invasion; loss of NFATC1 in EPDCs causes reduced coronary vessel and fibrous matrix penetration and embryonic lethality by E18.5.","method":"Conditional NFATC1 knockout in EPDCs, RANKL treatment of PE-derived cell cultures, in vivo CTSK expression analysis, calcineurin inhibitor experiments","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific phenotype, target gene (CTSK) identified, pharmacological and genetic validation, multiple approaches","pmids":["21447555"],"is_preprint":false},{"year":2009,"finding":"NFATc1 is required for lymphatic endothelial development; in NFATc1-null mice, lymphatic endothelial cells fail to properly coalesce into lymph sacs; calcineurin inhibition with cyclosporin A reduces podoplanin and FGFR-3 expression in lymphatics; NFATc1 siRNA reduces VEGFR-3 and podoplanin expression and NFATc1 activates lymphatic-specific gene promoters.","method":"NFATc1 knockout mouse analysis, cyclosporin A treatment in utero, siRNA knockdown, reporter assays, immunofluorescence co-localization","journal":"Mechanisms of development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic ablation plus pharmacological inhibition plus siRNA plus reporter assays, multiple orthogonal approaches","pmids":["19233265"],"is_preprint":false},{"year":2013,"finding":"Cartilage-specific ablation of NFATc1 in NFATc2-deficient mice leads to early onset aggressive osteoarthritis with loss of proteoglycans, collagen/aggrecan degradation, osteophyte formation, and joint instability, indicating NFATc1 and NFATc2 cooperate to repress spontaneous OA in chondrocytes.","method":"Cartilage-specific NFATc1 conditional knockout in NFATc2-/- mice, histomorphometry, micro-CT, analysis of human OA cartilage samples","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — double genetic ablation with specific phenotype, histological and structural phenotyping, corroborated by human tissue data","pmids":["24248346"],"is_preprint":false},{"year":2016,"finding":"IKKε phosphorylates NFATc1 during T cell activation, promoting its cytoplasmic retention and inhibiting T cell antitumor and antiviral immune responses; loss of IKKε elevates T cell immunity, while constitutively nuclear NFATc1 restores sorafenib resistance in IKKε-activated contexts.","method":"Kinase assay, T cell activation assays, IKKε knockout mice, tumor and viral infection models","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct kinase assay for phosphorylation plus in vivo genetic knockout, single lab","pmids":["27346349"],"is_preprint":false},{"year":2017,"finding":"NFATc1 controls cytotoxic T lymphocyte effector functions including cytoskeleton organization, recruitment of cytosolic organelles to immunological synapses, and glycolytic metabolic switching; NFATc1-deficient CD8+ T cells show impaired cytotoxicity and glycolysis that can be restored by IL-2. Genome-wide ChIP-seq confirms NFATc1 binding to genes controlling CTL activity including Tbx21 and Gzmb.","method":"Nfatc1 conditional KO in T cells, genome-wide ChIP-seq, transcriptome analysis, metabolic assays, in vivo infection/tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined cellular and metabolic phenotypes plus ChIP-seq, multiple orthogonal methods","pmids":["28894104"],"is_preprint":false},{"year":2017,"finding":"DYRK1A phosphorylates NFATc1/αA at S261, S278, S403, and S409, which interferes with NFATc1 ubiquitination and proteasomal degradation, thereby stabilizing the protein and increasing its transcriptional activity—contrary to its suppressive role on NFATc2.","method":"In vitro kinase assay with site-specific mutagenesis, ubiquitination assay, protein stability assay, transcriptional reporter assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis plus ubiquitination assay, single lab, multiple orthogonal methods","pmids":["28235034"],"is_preprint":false},{"year":2021,"finding":"SUMOylation of NFATc1 represses IL-2 production in T cells in vivo; transgenic mice in which NFATc1 SUMOylation is prevented show elevated IL-2, expanded regulatory T cells, and ameliorated autoimmune encephalomyelitis and graft-versus-host disease. Mechanistically, increased IL-2 counteracts IL-17/IFN-γ through STAT5 and Blimp-1 induction.","method":"SUMO-site mutant transgenic mouse generation, in vivo EAE and GVHD models, cytokine and transcription factor analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic mouse with defined SUMO-site mutation, multiple in vivo disease models, mechanistic pathway dissection","pmids":["32986812"],"is_preprint":false},{"year":2019,"finding":"STAT3 drives NFATc1 transcription by directly binding to the NFATc1 promoter in osteoclast precursors; conditional deletion of Stat3 in osteoclasts reduces NFATc1 expression and impairs osteoclast differentiation, and enforced NFATc1 expression rescues the Stat3-deficient differentiation defect.","method":"Osteoclast-specific Stat3 conditional knockout (Ctsk-Cre), promoter binding by ChIP, NFATc1 rescue experiments, STAT3 inhibitor (AG490)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus ChIP plus rescue experiment, multiple orthogonal approaches, epistasis established","pmids":["31462535"],"is_preprint":false},{"year":2014,"finding":"NFATc1 directly binds the Itpr2 promoter and regulates InsP3R2 (type 2 IP3 receptor) gene expression in cardiomyocytes; calcineurin-NFATc1 signaling upregulates InsP3R2 in cardiac hypertrophy, forming a positive feedback loop because InsP3R2-mediated Ca2+ release activates calcineurin-NFATc.","method":"Promoter-reporter assay, chromatin immunoprecipitation, calcineurin transgenic mice, calcineurin inhibitor studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct promoter binding by ChIP plus functional reporter plus transgenic mouse model, multiple orthogonal methods","pmids":["24415751"],"is_preprint":false},{"year":2009,"finding":"FOXP3 competes with NFAT1 for binding to the endogenous NFAT2 (NFATc1) promoter, suppressing NFAT2 transcription in regulatory T cells; ectopic NFAT2 expression in FOXP3+ Treg cells partially restores IL-2 production, indicating FOXP3-mediated NFAT2 repression contributes to the anergic phenotype.","method":"Chromatin immunoprecipitation, inducible FOXP3 expression, retroviral NFAT2 overexpression, promoter reporter assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP showing competitive promoter occupancy plus functional rescue by ectopic NFAT2, multiple orthogonal methods","pmids":["19564342"],"is_preprint":false},{"year":2014,"finding":"NF-κB1/p50 and c-Rel control the induction of NFATc1/αA in BCR-stimulated B cells via two composite κB/NFAT-binding sites in the inducible Nfatc1 P1 promoter.","method":"B cell-specific NF-κB knockouts, promoter-reporter assays with binding site analysis, BCR stimulation experiments","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockouts plus promoter reporter with binding site analysis, single lab","pmids":["25179582"],"is_preprint":false},{"year":2024,"finding":"Transient activation of the serine synthesis pathway (SSP) is required for osteoclastogenesis; SSP-derived α-ketoglutarate is necessary for histone demethylases that remove repressive histone methylation marks at the Nfatc1 gene locus, thereby inducing NFATc1 expression and osteoclast maturation. Deletion of the rate-limiting SSP enzyme phosphoglycerate dehydrogenase in osteoclast progenitors impairs differentiation.","method":"Osteoclast progenitor-specific PHGDH deletion, chromatin/histone methylation analysis, metabolite supplementation, OVX mouse model","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus epigenetic mechanistic dissection plus metabolite rescue, multiple orthogonal methods establishing metabolic-epigenetic coupling","pmids":["38200114"],"is_preprint":false},{"year":2023,"finding":"NFATc1 transcriptionally upregulates SLC7A11 (xCT) during RANKL-induced osteoclastogenesis, increasing cystine import in osteoclast precursors; during TXNRD1 inhibition this causes cystine accumulation and disulfidptosis, selectively killing osteoclast precursors over BMDMs.","method":"NFATc1 ChIP/transcriptional assay for SLC7A11 promoter, TXNRD1 inhibitor treatment, rescue with SLC7A11 inhibitors, OVX mouse model","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP/transcriptional regulation plus pharmacological rescue experiments, single lab","pmids":["37148740"],"is_preprint":false},{"year":2012,"finding":"Cot (Tpl-2) serine/threonine kinase directly phosphorylates NFATc1 (and all other NFATc family members) and increases NFATc1 protein stability, promoting Ca2+ oscillation/calcineurin-independent osteoclastogenesis through osteoblast-osteoclast cell-cell contact.","method":"In vitro kinase assay, co-culture system, Cot overexpression/knockdown, NFATc1 stability assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay plus protein stability assay plus cell-based functional validation, single lab with multiple orthogonal methods","pmids":["22615493"],"is_preprint":false},{"year":2005,"finding":"CCR1 is a direct transcriptional target of NFATc1/NFAT2 during RANKL-induced osteoclastogenesis; the CCR1 upstream regulatory region shows RANKL-dependent, cyclosporin A-suppressible promoter activity; CCR1 signaling downstream of NFAT2 enhances migration of differentiating osteoclasts.","method":"Microarray analysis, quantitative RT-PCR, luciferase promoter reporter assay, CCR1 siRNA, Boyden chamber migration assay","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter with pharmacological validation plus siRNA functional assay, single lab","pmids":["16355273"],"is_preprint":false},{"year":2007,"finding":"NFATc (NFATc4 expressed in tendons) binds TSE1 in nuclear extracts from tendon fibroblasts and transactivates the COL1a1 promoter through this element; inhibition of NFATc nuclear translocation strongly inhibits COL1a1 gene expression, suggesting NFATc and scleraxis cooperate to activate type I collagen expression specifically in tendon fibroblasts.","method":"Gel shift assay (EMSA), transfection/reporter assays, pharmacological NFATc nuclear translocation inhibition","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus reporter assay plus functional inhibition, single lab, note this study focuses on NFATc4 not NFATc1 specifically","pmids":["17430895"],"is_preprint":false},{"year":2007,"finding":"NFATc1 is required for TGF-β-mediated transcriptional induction of fibronectin in mesangial cells; constitutively active calcineurin increases fibronectin transcription, and dominant-negative NFATc or NFATc1 inhibition blocks TGF-β-mediated fibronectin promoter activation.","method":"Calcineurin inhibitors, constitutively active calcineurin overexpression, dominant-negative NFATc expression, promoter reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss of function approaches with promoter reporter, single lab","pmids":["17719012"],"is_preprint":false},{"year":2013,"finding":"High glucose activates NFATc1 (NFAT2) in podocytes via increased intracellular Ca2+ leading to calcineurin activation, and NFATc1 mediates podocyte apoptosis through transcriptional upregulation of Bax; calcineurin/NFAT2 inhibition blocks both nuclear accumulation and apoptosis.","method":"Immunofluorescence, western blot, flow cytometry, Ca2+ imaging with Fluo-3/AM, calcineurin inhibitors, NFAT2-specific inhibitor (11R-VIVIT)","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple complementary methods establishing Ca2+/calcineurin/NFATc1/Bax pathway, single lab","pmids":["23340267"],"is_preprint":false},{"year":2012,"finding":"The calcineurin/NFATc1 signaling pathway promotes HCC cell proliferation; calcineurin-regulated NFATc1 nuclear import/export is demonstrated in HepG2 cells, and NFATc1 knockdown causes G1 cell cycle arrest and reduces c-Myc and COX-2 expression, suggesting NFATc1 drives proliferation through these oncogenes.","method":"NFATc1 siRNA knockdown, immunofluorescence, western blot, flow cytometry cell cycle analysis, ionomycin/cyclosporin A treatment","journal":"Digestive diseases and sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with downstream target analysis, multiple assays, single lab","pmids":["22722879"],"is_preprint":false},{"year":2015,"finding":"NFATc1 drives EMT reprogramming and maintains pancreatic cancer cells in a stem cell-like state through Sox2-dependent transcription of EMT and stemness factors; NFATc1-Sox2 complex-mediated dedifferentiation is opposed by p53-miR200c signaling, and inactivation of the p53 pathway is required for NFATc1-driven tumor dedifferentiation.","method":"NFATc1 gain/loss of function, Sox2 co-expression analysis, genetically engineered mouse models, transcriptional reporter assays, human PDAC analysis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional experiments in cell lines and GEMM with mechanistic link to Sox2, single lab","pmids":["25586376"],"is_preprint":false},{"year":2023,"finding":"The deubiquitinase UCHL1 deubiquitinates and stabilizes TAZ at K46 by removing K48-linked polyubiquitination; stabilized TAZ inhibits NFATc1 dephosphorylation and nuclear transport by competing with calcineurin A for binding to NFATc1, thereby negatively regulating osteoclastogenesis.","method":"Osteoclast-specific UCHL1 conditional KO, proteomic analysis, ubiquitination assay, Co-IP (TAZ-calcineurin-NFATc1 competition), OVX mouse model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO plus Co-IP competition assay plus ubiquitination biochemistry, single lab","pmids":["37215988"],"is_preprint":false},{"year":2020,"finding":"Zebrafish Nfatc1 is required for valve interstitial cell (VIC) formation in cardiac valve development by promoting proliferation and endocardial/neural crest cell recruitment; Nfatc1 promotes expression of twist1b (a regulator of endothelial-to-mesenchymal transition) as a downstream effector; loss of Nfatc1 results in valvular dysfunction with persistent retrograde blood flow.","method":"Zebrafish nfatc1 mutants, live imaging, high-speed microscopy, echocardiography, transcriptional target analysis","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with live imaging, downstream effector identified, single lab","pmids":["32070236"],"is_preprint":false},{"year":2019,"finding":"NFAT2 (NFATc1) is a critical regulator of the anergic phenotype in CLL B cells; B cell-specific ablation of Nfat2 leads to loss of anergy and transformation to aggressive disease; NFAT2-dependent gene expression signature includes Cbl-b, Grail, Egr2, and Lck.","method":"B cell-specific Nfat2 conditional knockout mouse CLL models, gene expression analysis, human CLL biopsy analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in disease model with defined gene signature and human corroboration, multiple approaches","pmids":["28970470"],"is_preprint":false},{"year":2014,"finding":"NFATc1 activity is required for early B cell development; loss of NFATc1 in pro-B cells suppresses EBF1 expression, impairs immunoglobulin gene rearrangement and preBCR formation, arresting pro-B to pre-B cell transition and causing severe B cell lymphopenia.","method":"Multiple NFATc1-deficient mouse models, bone marrow analysis, flow cytometry, immunoglobulin rearrangement assays","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic mouse models with specific molecular mechanism (EBF1 suppression, Ig rearrangement impairment) identified","pmids":["29907883"],"is_preprint":false},{"year":2022,"finding":"NFATc1 drives NAFLD progression through chronic ER stress sensing and activation of the PERK-CHOP unfolded protein response pathway in hepatocytes; hepatocyte-specific NFATc1 depletion prevents disease acceleration in high-fat western diet-fed mice, and NFATc1-induced NASH progression can be blocked by TUDCA.","method":"Hepatocyte-specific NFATc1 transgenic/KO mice, western diet feeding, UPR pathway analysis, TUDCA treatment, human NAFLD patient samples","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO and overexpression plus mechanistic UPR pathway analysis plus pharmacological rescue, human tissue corroboration","pmids":["35365570"],"is_preprint":false},{"year":2014,"finding":"NFATc1 regulates dexamethasone-induced myocilin (MYOC) expression in human trabecular meshwork cells via calcineurin activation; dexamethasone causes calcium-independent NFATc1 nuclear translocation within 15 minutes, and both calcineurin inhibitors and NFATc1 siRNA block DEX-induced MYOC mRNA increase.","method":"Calcineurin inhibitors (cyclosporin A, INCA-6), NFATc1 siRNA, immunofluorescence nuclear translocation assay, qRT-PCR","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown plus pharmacological inhibition plus nuclear translocation assay, single lab","pmids":["25450062"],"is_preprint":false},{"year":2013,"finding":"NFATc1 regulates TRAIL expression in intestinal cells by activating the TRAIL promoter and negatively regulating Sp1 binding to the TRAIL promoter; knockdown of NFATc1 increases Sp1 binding and inhibition of Sp1 increases TRAIL expression, indicating an indirect regulatory mechanism.","method":"NFATc1 knockdown, Sp1 inhibition, promoter activity assay, chromatin analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus Sp1 binding analysis plus dual knockdown approach, single lab","pmids":["21603612"],"is_preprint":false},{"year":2004,"finding":"IL-2 and IL-15 oppositely regulate CX3CR1 expression through differential recruitment of NFAT2 versus NFAT1 to a κB-like NFAT site in the CX3CR1 promoter; IL-2 promotes NFAT2 binding while IL-15 promotes NFAT1 binding, as demonstrated by ChIP.","method":"Chromatin immunoprecipitation, NFAT1-/- mice, promoter mutation assays, luciferase reporter in PBMCs, NFAT inhibitor experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for differential promoter occupancy plus genetic mouse model plus promoter mutation plus pharmacological inhibition, multiple orthogonal approaches","pmids":["15347678"],"is_preprint":false},{"year":2019,"finding":"CR3 engagement by M. leprae PGL-I activates the Syk tyrosine kinase, which induces calcineurin-dependent nuclear translocation of NFATc in innate immune cells (macrophages, neutrophils, dendritic cells), selectively augmenting production of IL-2 (DCs), IL-10 (PMNs), and IL-1β (macrophages).","method":"CR3 engagement assays, Syk inhibition, calcineurin inhibition, NFATc nuclear translocation imaging, cytokine measurements, intranasal infection model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with in vivo infection model, single lab","pmids":["31921172"],"is_preprint":false},{"year":2012,"finding":"NFATc1-mediated calcineurin signaling activation in mesangial cells drives uPAR-ITGB3 pathway activation; calcineurin-NFATC inhibition by miR-30 family blocks this pathway. In cultured podocytes, calcineurin-NFATC signaling activates the uPAR-ITGB3 pathway, leading to Rho GTPase activation, synaptopodin downregulation, and cytoskeletal injury.","method":"Podocyte-specific miR-30 KO, calcineurin/NFATC inhibitors, Transwell co-culture system, podocyte-specific transgenic miR-30, cytoskeletal assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO plus pharmacological inhibition plus transgenic rescue, single lab","pmids":["31127093"],"is_preprint":false},{"year":2017,"finding":"KCa3.1 (a Ca2+-activated K+ channel) modulates Ca2+-induced NFATc1 activation during inflammatory osteoclastogenesis via the CaMKIV/CREB/c-Fos axis; KCa3.1 deficiency or TRAM-34 blockade reduces RANKL-induced Ca2+ transient amplitudes by ~50% and decreases NFATc1 expression and transcriptional activity.","method":"KCa3.1 knockout mice, TRAM-34 pharmacological inhibition, live cell Ca2+ imaging, western blot for pathway components, BMM culture osteoclastogenesis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus live Ca2+ imaging plus pathway western blots, single lab","pmids":["29246953"],"is_preprint":false},{"year":2023,"finding":"The short NFATc1/αA isoform is essential for osteoclastogenesis and self-regulation; NFATc1/αA-specific knockout mice die in utero by E13.5, and in a novel hematopoietic stem cell differentiation culture system, loss of NFATc1/αA impairs osteoclast differentiation and expression of osteoclast markers and Nfatc1 regulators.","method":"Short-isoform-specific NFATc1/αA knockout mouse, novel HSC-to-osteoclast in vitro culture system, gene expression analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific genetic KO with functional differentiation assay, single lab","pmids":["37914750"],"is_preprint":false},{"year":2020,"finding":"Homer2 and Homer3 regulate NFATc1 function in osteoclastogenesis by interacting with NFATc1 and competing with its activation by calcineurin; RANKL treatment inhibits Homer-NFATc1 interaction, which is restored by calcineurin inhibition (cyclosporin A). Homer2/3 double knockout markedly decreases bone density.","method":"Homer2/3 double knockout mice, BMM osteoclastogenesis assay, Co-IP of Homer-NFATc1, calcineurin inhibitor experiments, micro-CT","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus Co-IP demonstrating physical interaction, single lab","pmids":["31319381"],"is_preprint":false},{"year":2002,"finding":"GATA5 and NF-ATc (NFATc1) synergistically activate endocardial transcription; inhibition of either GATA5 expression or NF-ATc activation blocks terminal endothelial-endocardial differentiation at a pre-endocardial stage in an in vitro model of cardiogenic differentiation.","method":"In vitro cardiogenic differentiation model, calcineurin/NF-ATc inhibition, GATA5 expression manipulation, transcriptional reporter assays","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro differentiation model with loss-of-function for both factors plus synergy reporter assays, single lab","pmids":["12163407"],"is_preprint":false},{"year":2013,"finding":"NFATc1 (NFAT2) suppresses E-cadherin expression by transcriptionally upregulating Snail and Zeb1 in a TGF-β-independent manner, promoting cancer cell invasion; inducible constitutively active NFATc1 expression promotes invasion in A549 and MCF7 cells and in tumor xenografts in vivo.","method":"Inducible constitutively active NFATc1 expression, RNA interference, cell invasion assay, tumor xenograft, gene expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible expression with identified downstream targets plus in vivo xenograft validation, single lab","pmids":["23811942"],"is_preprint":false},{"year":2013,"finding":"NFAT2 regulates HDAC1 transcriptional activity in glioblastoma stem cells; NFAT2-HDAC1 signaling maintains the mesenchymal phenotype, and loss of both NFAT2 and HDAC1 causes hyperacetylation of NF-κB, inhibiting NF-κB-dependent transcription.","method":"NFAT2 siRNA knockdown, HDAC1 rescue experiments, NFAT2 overexpression, NF-κB acetylation analysis, in vivo tumorigenicity","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown plus rescue plus downstream pathway analysis, single lab","pmids":["31400279"],"is_preprint":false},{"year":2019,"finding":"RBP-J represses while NFATc1 activates miR182 expression in TNF-induced osteoclastogenesis through binding to specific open chromatin regions in the miR182 promoter; this RBP-J/NFATc1-miR182 regulatory network controls the balance between activating and repressive signals in inflammatory osteoclastogenesis.","method":"ChIP for NFATc1 and RBP-J binding to miR182 promoter, miR182 inhibition, open chromatin analysis, in vivo inflammatory arthritis model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for promoter binding plus functional miRNA experiments, single lab","pmids":["31908034"],"is_preprint":false}],"current_model":"NFATc1 is a Ca2+/calcineurin-regulated transcription factor that, upon dephosphorylation by calcineurin at conserved Ser-Pro repeat motifs, translocates to the nucleus where it acts as a master transcriptional regulator of osteoclast differentiation (downstream of RANKL-TRAF6-c-Fos) and controls diverse processes including T and B lymphocyte activation and differentiation, hair follicle stem cell quiescence (via CDK4 repression), cardiac valve and lymphatic development, and glycolytic/metabolic reprogramming; its activity is negatively regulated by multiple kinases (GSK-3, JNK, ERK, p38, CK2, IKKε, DYRK1A) that phosphorylate it to drive nuclear export or proteasomal degradation, and by post-translational SUMOylation that represses IL-2 production, while Cot kinase and DYRK1A can stabilize NFATc1 protein through phosphorylation-mediated interference with ubiquitination."},"narrative":{"mechanistic_narrative":"NFATc1 is a Ca2+/calcineurin-regulated transcription factor whose DNA-binding domain adopts a Rel-like fold that recognizes target promoters and cooperates with partner factors such as AP-1 on composite elements [PMID:8990122]. Its activity is gated by phosphorylation: GSK-3, JNK, ERK, p38, CK2, and IKKε associate with and phosphorylate conserved Ser-Pro repeat motifs and Ser172 in the N-terminal regulatory domain, opposing calcineurin-mediated dephosphorylation by promoting cytoplasmic retention/nuclear export and reducing intrinsic DNA binding, while calcineurin dephosphorylation drives nuclear import and enhances DNA binding [PMID:9072970, PMID:11063740, PMID:10652349, PMID:27346349]. Protein abundance is further tuned by phosphorylation-dependent stabilization through Cot/Tpl-2 and DYRK1A (which block ubiquitination) and by SUMOylation that represses IL-2 output [PMID:28235034, PMID:32986812, PMID:22615493]. The best-defined biological role of NFATc1 is as the master transcriptional switch for terminal osteoclast differentiation downstream of RANKL-TRAF6-c-Fos and Ca2+/calcineurin signaling [PMID:12479813]; its induction at the Nfatc1 locus depends on STAT3 and on serine-synthesis-derived α-ketoglutarate that feeds histone demethylases to remove repressive marks, and it drives an osteoclastogenic gene program including CCR1, SLC7A11, and miR182 [PMID:31462535, PMID:38200114, PMID:37148740, PMID:16355273, PMID:31908034]. Beyond bone, NFATc1 governs lymphocyte development and function—B-1a cell development, pro-B to pre-B transition via EBF1, cytotoxic T cell effector functions and glycolytic reprogramming, follicular regulatory T cell homing via CXCR5, and anergy programs—and it controls cardiac valve, lymphatic, and epicardial development, hair follicle stem cell quiescence through CDK4 repression, and disease-associated transcriptional programs in cancer and metabolic/fibrotic tissues [PMID:18243104, PMID:24590764, PMID:14595020, PMID:19233265, PMID:28894104, PMID:32070236, PMID:28970470, PMID:29907883, PMID:35365570].","teleology":[{"year":1997,"claim":"Established how NFATc activity is negatively controlled, identifying GSK-3 as a kinase that phosphorylates the conserved N-terminal serines to drive nuclear export and oppose Ca2+-calcineurin import.","evidence":"Biochemical purification of NF-AT kinase and in vitro phosphorylation with nuclear localization assays","pmids":["9072970"],"confidence":"High","gaps":["Did not map all physiological GSK-3 priming events","In vivo relevance to specific tissues not addressed"]},{"year":1997,"claim":"Defined the structural basis of NFATc DNA recognition, showing a Rel-like DBD necessary and sufficient for binding and cooperative activation distinct from NF-κB p50.","evidence":"NMR solution structure with DNA binding and transcriptional activation assays","pmids":["8990122"],"confidence":"High","gaps":["No structure of full-length protein or partner co-complexes","AP-1 cooperativity modeled but not crystallographically resolved"]},{"year":2000,"claim":"Extended kinase regulation by showing GSK-3 and MAPKs/CK2 phosphorylation controls not only localization but also intrinsic DNA binding, and that multiple kinases physically dock on the N-terminal domain to block nuclear translocation.","evidence":"EMSA, in vitro kinase assays, Co-IP, mutant analysis, and subcellular localization assays","pmids":["11063740","10652349"],"confidence":"High","gaps":["Stoichiometry and ordering of multi-kinase phosphorylation unresolved","Phosphatase counteraction kinetics not defined"]},{"year":1999,"claim":"Showed NFATc1 isoform diversity generates distinct transactivation capacities, with isoform C containing a second TAD and isoform B exerting suppression.","evidence":"Alternative splicing analysis, TAD mapping, reporter and phosphorylation assays in T cells","pmids":["10358178"],"confidence":"Medium","gaps":["Single lab characterization","Tissue-specific isoform usage not mapped"]},{"year":2002,"claim":"Identified NFATc1 as the master transcriptional switch for terminal osteoclast differentiation downstream of RANKL-TRAF6-c-Fos and Ca2+/calcineurin signaling.","evidence":"NFATc1-deficient ES cell differentiation, ectopic expression, Ca2+ imaging, pathway genetics","pmids":["12479813"],"confidence":"High","gaps":["Full downstream target program not enumerated at the time","Mechanism of sustained autoamplification not detailed"]},{"year":2002,"claim":"Clarified that disparate NFATc1 vs NFATc2 cytokine phenotypes arise from differential regulation rather than intrinsic transcriptional differences at IL-4.","evidence":"Constitutively active alanine-substitution mutants with IL-4 transcription assays in T cells","pmids":["12355451"],"confidence":"Medium","gaps":["Single transcriptional readout","Differential upstream regulation not directly dissected"]},{"year":2002,"claim":"Demonstrated NFATc1 cooperates with GATA5 to drive endocardial differentiation, linking it to early cardiac development.","evidence":"In vitro cardiogenic differentiation with loss-of-function and synergy reporter assays","pmids":["12163407"],"confidence":"Medium","gaps":["In vitro model only","Direct target genes not identified"]},{"year":2008,"claim":"Revealed a repressive transcriptional role in stem cell maintenance, with NFATc1 repressing CDK4 to keep hair follicle stem cells quiescent downstream of BMP.","evidence":"Conditional and complete gene ablation, calcineurin inhibition, reporter/ChIP for CDK4","pmids":["18243104"],"confidence":"High","gaps":["Co-repressor machinery at CDK4 not defined","Generalizability to other stem cell niches untested"]},{"year":2003,"claim":"Established a cell-intrinsic, NFATc1-specific (vs NFATc2) requirement for B-1a cell development.","evidence":"NFATc1- and NFATc2-deficient mice, mixed chimeras, retroviral rescue, flow cytometry","pmids":["14595020"],"confidence":"High","gaps":["Direct B-1a target genes not identified","Isoform responsible not resolved"]},{"year":2009,"claim":"Defined cross-regulation among NFAT family members and FOXP3, showing FOXP3 competes with NFAT1 at the NFATc1 promoter to enforce Treg anergy, and IL-2/IL-15 differentially recruit NFAT2 vs NFAT1 to target promoters.","evidence":"ChIP, inducible FOXP3 expression, retroviral rescue, promoter mutation, NFAT1-/- mice","pmids":["19564342","15347678"],"confidence":"High","gaps":["Determinants of family-member-selective recruitment unresolved","In vivo competition dynamics not quantified"]},{"year":2011,"claim":"Extended NFATc1 to developmental ECM remodeling, showing RANKL/calcineurin-NFATC1 induces cathepsin K to enable epicardium-derived cell invasion.","evidence":"Conditional EPDC knockout, RANKL treatment, in vivo CTSK analysis, calcineurin inhibition","pmids":["21447555"],"confidence":"High","gaps":["Direct CTSK promoter occupancy not shown","Other invasion effectors not enumerated"]},{"year":2009,"claim":"Established a requirement for NFATc1 in lymphatic endothelial coalescence and lymphatic gene expression.","evidence":"Knockout mice, in utero cyclosporin A, siRNA, reporter assays, immunofluorescence","pmids":["19233265"],"confidence":"High","gaps":["Direct vs indirect regulation of VEGFR-3/podoplanin not separated","Upstream activator in lymphatics unclear"]},{"year":2013,"claim":"Connected calcineurin-NFATc1 signaling to disease-driving transcriptional programs across multiple tissues including cardiac hypertrophy feedback (Itpr2), chondroprotection, podocyte apoptosis (Bax), and cancer invasion.","evidence":"ChIP/promoter assays, transgenic and conditional KO mice, inducible constitutively active NFATc1, invasion and apoptosis assays","pmids":["24415751","24248346","23340267","23811942"],"confidence":"High","gaps":["Context-specific cofactors driving opposite (activating vs repressive) outputs unresolved","Several cancer findings are single-lab Medium-confidence"]},{"year":2014,"claim":"Mapped upstream transcriptional induction of NFATc1 itself in B cells (NF-κB1/p50 and c-Rel at the P1 promoter) and defined its role in early B cell development via EBF1 and immunoglobulin rearrangement.","evidence":"B cell-specific NF-κB and NFATc1 knockouts, promoter-reporter binding-site analysis, Ig rearrangement assays","pmids":["25179582","29907883"],"confidence":"High","gaps":["Direct EBF1 promoter occupancy by NFATc1 not shown","Isoform-specific contributions not separated"]},{"year":2014,"claim":"Defined NFATc1 control of follicular regulatory T cell positioning via CXCR5 upregulation, with autoimmune consequences.","evidence":"T cell-specific Nfat2 conditional knockout, immunization, flow cytometry, disease scoring","pmids":["24590764"],"confidence":"High","gaps":["Direct Cxcr5 promoter binding not demonstrated","Cofactor requirements in TFR cells unknown"]},{"year":2016,"claim":"Identified IKKε as an additional negative regulatory kinase retaining NFATc1 in the cytoplasm to dampen T cell antitumor/antiviral immunity.","evidence":"Kinase assay, T cell activation assays, IKKε knockout mice, tumor/viral models","pmids":["27346349"],"confidence":"Medium","gaps":["Phosphosite mapping incomplete","Single lab"]},{"year":2017,"claim":"Showed NFATc1 directly programs cytotoxic T cell effector function, synapse organization, and glycolytic metabolic switching, with genome-wide target identification including Tbx21 and Gzmb.","evidence":"Conditional T cell KO, ChIP-seq, transcriptomics, metabolic assays, in vivo models","pmids":["28894104"],"confidence":"High","gaps":["Direct vs indirect metabolic gene targets not fully separated","IL-2 rescue mechanism not fully resolved"]},{"year":2017,"claim":"Resolved a paradoxical positive post-translational regulation: DYRK1A phosphorylation at specific serines blocks NFATc1 ubiquitination and stabilizes it, opposite to its effect on NFATc2.","evidence":"In vitro kinase assay with site mutagenesis, ubiquitination assay, stability and reporter assays","pmids":["28235034"],"confidence":"Medium","gaps":["E3 ligase blocked by phosphorylation not identified","In vivo relevance limited"]},{"year":2019,"claim":"Established STAT3 as a direct transcriptional activator of the Nfatc1 gene in osteoclast precursors, placing NFATc1 induction within a defined upstream cascade.","evidence":"Osteoclast-specific Stat3 conditional KO, ChIP, NFATc1 rescue, STAT3 inhibitor","pmids":["31462535"],"confidence":"High","gaps":["Interplay with calcineurin-driven autoamplification not dissected","Other STAT3 cofactors at the locus unknown"]},{"year":2021,"claim":"Demonstrated SUMOylation as a physiological brake on NFATc1, repressing IL-2 to limit Treg expansion and autoimmunity in vivo.","evidence":"SUMO-site mutant transgenic mice, EAE and GVHD models, cytokine/TF analysis","pmids":["32986812"],"confidence":"High","gaps":["SUMO E3 ligase and target lysines mechanistic detail limited","Tissue-specificity of SUMO regulation not mapped"]},{"year":2023,"claim":"Uncovered additional layers of stability control and metabolic gene coupling, including UCHL1-TAZ competition with calcineurin for NFATc1 and NFATc1-driven SLC7A11 import linking osteoclast precursors to disulfidptosis.","evidence":"Conditional KOs, Co-IP competition, ubiquitination biochemistry, ChIP, pharmacological rescue, OVX models","pmids":["37215988","37148740"],"confidence":"Medium","gaps":["Single-lab findings","Direct structural basis of TAZ-calcineurin competition for NFATc1 not resolved"]},{"year":2024,"claim":"Linked metabolism to NFATc1 induction epigenetically, showing serine-synthesis-derived α-ketoglutarate is required for histone demethylation at the Nfatc1 locus during osteoclastogenesis.","evidence":"Osteoclast progenitor PHGDH deletion, histone methylation analysis, metabolite rescue, OVX model","pmids":["38200114"],"confidence":"High","gaps":["Specific demethylases acting at the locus not definitively assigned","Generalizability beyond osteoclasts untested"]},{"year":null,"claim":"How tissue- and context-specific cofactors switch NFATc1 between transcriptional activation and repression of overlapping target sets, and how the full network of stabilizing vs destabilizing post-translational modifications is integrated in vivo, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of activator-vs-repressor output selection","E3 ligases and SUMO machinery acting on NFATc1 incompletely defined","Isoform-specific functional division of labor not comprehensively mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,7,17,32,35,47]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,4,7,21]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,5,31]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,3,16]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,3,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,7,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11,17,35,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[13,14,34,46]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,24,37]}],"complexes":[],"partners":["PPP3CA","GSK3B","DYRK1A","FOXP3","SOX2","HOMER2","HOMER3","TAZ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95644","full_name":"Nuclear factor of activated T-cells, cytoplasmic 1","aliases":["NFAT transcription complex cytosolic component","NF-ATc","NFATc"],"length_aa":943,"mass_kda":101.2,"function":"Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation and proliferation but also the differentiation and programmed death of T-lymphocytes as well as lymphoid and non-lymphoid cells (PubMed:10358178). Required for osteoclastogenesis and regulates many genes important for osteoclast differentiation and function (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/O95644/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFATC1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NFATC1","total_profiled":1310},"omim":[{"mim_id":"621356","title":"SH3 AND CYSTEINE-RICH DOMAINS 2; STAC2","url":"https://www.omim.org/entry/621356"},{"mim_id":"620638","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 4; KCTD4","url":"https://www.omim.org/entry/620638"},{"mim_id":"620432","title":"OSTEOCLAST STIMULATORY TRANSMEMBRANE PROTEIN; OCSTAMP","url":"https://www.omim.org/entry/620432"},{"mim_id":"618749","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 17; LRRC17","url":"https://www.omim.org/entry/618749"},{"mim_id":"617514","title":"IMMUNODEFICIENCY 52; IMD52","url":"https://www.omim.org/entry/617514"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"choroid plexus","ntpm":33.8}],"url":"https://www.proteinatlas.org/search/NFATC1"},"hgnc":{"alias_symbol":["NF-ATC","NFATc","NFAT2"],"prev_symbol":[]},"alphafold":{"accession":"O95644","domains":[{"cath_id":"2.60.40.340","chopping":"423-587","consensus_level":"high","plddt":91.9661,"start":423,"end":587},{"cath_id":"2.60.40.10","chopping":"598-695","consensus_level":"high","plddt":93.2293,"start":598,"end":695}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95644","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95644-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95644-F1-predicted_aligned_error_v6.png","plddt_mean":56.78},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFATC1","jax_strain_url":"https://www.jax.org/strain/search?query=NFATC1"},"sequence":{"accession":"O95644","fasta_url":"https://rest.uniprot.org/uniprotkb/O95644.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95644/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95644"}},"corpus_meta":[{"pmid":"12479813","id":"PMC_12479813","title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.","date":"2002","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/12479813","citation_count":2090,"is_preprint":false},{"pmid":"9072970","id":"PMC_9072970","title":"Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9072970","citation_count":626,"is_preprint":false},{"pmid":"25489571","id":"PMC_25489571","title":"Regulation of NFATc1 in Osteoclast Differentiation.","date":"2014","source":"Journal of bone metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25489571","citation_count":443,"is_preprint":false},{"pmid":"18243104","id":"PMC_18243104","title":"NFATc1 balances quiescence and proliferation of skin stem cells.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18243104","citation_count":350,"is_preprint":false},{"pmid":"18802087","id":"PMC_18802087","title":"NFATc1 regulates PD-1 expression upon T cell activation.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18802087","citation_count":334,"is_preprint":false},{"pmid":"10549622","id":"PMC_10549622","title":"Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10549622","citation_count":249,"is_preprint":false},{"pmid":"20035895","id":"PMC_20035895","title":"NFATc1: functions in osteoclasts.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20035895","citation_count":197,"is_preprint":false},{"pmid":"17430895","id":"PMC_17430895","title":"Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17430895","citation_count":194,"is_preprint":false},{"pmid":"31367247","id":"PMC_31367247","title":"Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31367247","citation_count":176,"is_preprint":false},{"pmid":"28894104","id":"PMC_28894104","title":"NFATc1 controls the cytotoxicity of CD8+ T cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28894104","citation_count":170,"is_preprint":false},{"pmid":"7650004","id":"PMC_7650004","title":"NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7650004","citation_count":161,"is_preprint":false},{"pmid":"11581284","id":"PMC_11581284","title":"Activity-dependent nuclear translocation and intranuclear distribution of NFATc in adult skeletal muscle fibers.","date":"2001","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11581284","citation_count":146,"is_preprint":false},{"pmid":"24590764","id":"PMC_24590764","title":"Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24590764","citation_count":141,"is_preprint":false},{"pmid":"12810687","id":"PMC_12810687","title":"Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12810687","citation_count":134,"is_preprint":false},{"pmid":"11063740","id":"PMC_11063740","title":"Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11063740","citation_count":130,"is_preprint":false},{"pmid":"10652349","id":"PMC_10652349","title":"Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10652349","citation_count":124,"is_preprint":false},{"pmid":"7650486","id":"PMC_7650486","title":"Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7650486","citation_count":123,"is_preprint":false},{"pmid":"31431733","id":"PMC_31431733","title":"Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca2+-NFATc1 signaling pathway.","date":"2019","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/31431733","citation_count":108,"is_preprint":false},{"pmid":"12355451","id":"PMC_12355451","title":"NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12355451","citation_count":105,"is_preprint":false},{"pmid":"31462535","id":"PMC_31462535","title":"STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31462535","citation_count":96,"is_preprint":false},{"pmid":"8990122","id":"PMC_8990122","title":"Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8990122","citation_count":89,"is_preprint":false},{"pmid":"25586376","id":"PMC_25586376","title":"Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity.","date":"2015","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/25586376","citation_count":85,"is_preprint":false},{"pmid":"37148740","id":"PMC_37148740","title":"NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37148740","citation_count":82,"is_preprint":false},{"pmid":"22321691","id":"PMC_22321691","title":"Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling.","date":"2012","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/22321691","citation_count":82,"is_preprint":false},{"pmid":"32455661","id":"PMC_32455661","title":"The Role of Ca2+-NFATc1 Signaling and Its Modulation on Osteoclastogenesis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32455661","citation_count":81,"is_preprint":false},{"pmid":"17166937","id":"PMC_17166937","title":"Calcineurin-NFATc signaling pathway regulates AQP2 expression in response to calcium signals and osmotic stress.","date":"2006","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17166937","citation_count":81,"is_preprint":false},{"pmid":"12163407","id":"PMC_12163407","title":"Cooperative interaction between GATA5 and NF-ATc regulates endothelial-endocardial differentiation of cardiogenic cells.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12163407","citation_count":78,"is_preprint":false},{"pmid":"23826864","id":"PMC_23826864","title":"NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23826864","citation_count":75,"is_preprint":false},{"pmid":"10358178","id":"PMC_10358178","title":"Multiple NF-ATc isoforms with individual transcriptional properties are synthesized in T lymphocytes.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10358178","citation_count":70,"is_preprint":false},{"pmid":"24248346","id":"PMC_24248346","title":"NFATc1 and NFATc2 repress spontaneous osteoarthritis.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24248346","citation_count":67,"is_preprint":false},{"pmid":"16931157","id":"PMC_16931157","title":"NFATc1 autoregulation: a crucial step for cell-fate determination.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16931157","citation_count":62,"is_preprint":false},{"pmid":"34801352","id":"PMC_34801352","title":"Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34801352","citation_count":59,"is_preprint":false},{"pmid":"14595020","id":"PMC_14595020","title":"Normal B-1a cell development requires B cell-intrinsic NFATc1 activity.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14595020","citation_count":58,"is_preprint":false},{"pmid":"35365570","id":"PMC_35365570","title":"NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.","date":"2022","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/35365570","citation_count":56,"is_preprint":false},{"pmid":"19233265","id":"PMC_19233265","title":"NFATc1 regulates lymphatic endothelial development.","date":"2009","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/19233265","citation_count":55,"is_preprint":false},{"pmid":"23665018","id":"PMC_23665018","title":"AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23665018","citation_count":50,"is_preprint":false},{"pmid":"32070236","id":"PMC_32070236","title":"Nfatc1 Promotes Interstitial Cell Formation During Cardiac Valve Development in Zebrafish.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/32070236","citation_count":50,"is_preprint":false},{"pmid":"22722879","id":"PMC_22722879","title":"Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma.","date":"2012","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22722879","citation_count":49,"is_preprint":false},{"pmid":"21447555","id":"PMC_21447555","title":"NFATC1 promotes epicardium-derived cell invasion into myocardium.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21447555","citation_count":47,"is_preprint":false},{"pmid":"32454224","id":"PMC_32454224","title":"Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32454224","citation_count":45,"is_preprint":false},{"pmid":"23340267","id":"PMC_23340267","title":"NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23340267","citation_count":43,"is_preprint":false},{"pmid":"31400279","id":"PMC_31400279","title":"NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.","date":"2020","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31400279","citation_count":42,"is_preprint":false},{"pmid":"27346349","id":"PMC_27346349","title":"IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27346349","citation_count":42,"is_preprint":false},{"pmid":"38200114","id":"PMC_38200114","title":"The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression.","date":"2024","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38200114","citation_count":41,"is_preprint":false},{"pmid":"25976987","id":"PMC_25976987","title":"NFATc1 as a therapeutic target in FLT3-ITD-positive AML.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25976987","citation_count":41,"is_preprint":false},{"pmid":"28970470","id":"PMC_28970470","title":"NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28970470","citation_count":40,"is_preprint":false},{"pmid":"30827151","id":"PMC_30827151","title":"Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.","date":"2019","source":"The American journal of Chinese medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30827151","citation_count":38,"is_preprint":false},{"pmid":"24415751","id":"PMC_24415751","title":"Calcineurin-NFATc regulates type 2 inositol 1,4,5-trisphosphate receptor (InsP3R2) expression during cardiac remodeling.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24415751","citation_count":37,"is_preprint":false},{"pmid":"26477312","id":"PMC_26477312","title":"NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26477312","citation_count":37,"is_preprint":false},{"pmid":"19564342","id":"PMC_19564342","title":"FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19564342","citation_count":36,"is_preprint":false},{"pmid":"31183372","id":"PMC_31183372","title":"TRPV1 Induced Apoptosis of Colorectal Cancer Cells by Activating Calcineurin-NFAT2-p53 Signaling Pathway.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31183372","citation_count":36,"is_preprint":false},{"pmid":"36375645","id":"PMC_36375645","title":"Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice.","date":"2022","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36375645","citation_count":36,"is_preprint":false},{"pmid":"29056557","id":"PMC_29056557","title":"AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29056557","citation_count":35,"is_preprint":false},{"pmid":"30857415","id":"PMC_30857415","title":"Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF-κB-NFATc1 signal pathway.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30857415","citation_count":35,"is_preprint":false},{"pmid":"30328352","id":"PMC_30328352","title":"TRPM3/TRPV4 regulates Ca2+-mediated RANKL/NFATc1 expression in osteoblasts.","date":"2018","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30328352","citation_count":34,"is_preprint":false},{"pmid":"27723141","id":"PMC_27723141","title":"Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca2+ /NFATc1 Axis.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27723141","citation_count":34,"is_preprint":false},{"pmid":"30419283","id":"PMC_30419283","title":"MicroRNA-499-5p regulates skeletal myofiber specification via NFATc1/MEF2C pathway and Thrap1/MEF2C axis.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30419283","citation_count":34,"is_preprint":false},{"pmid":"15347678","id":"PMC_15347678","title":"Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15347678","citation_count":33,"is_preprint":false},{"pmid":"17719012","id":"PMC_17719012","title":"NFATc is required for TGFbeta-mediated transcriptional regulation of fibronectin.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17719012","citation_count":33,"is_preprint":false},{"pmid":"16355273","id":"PMC_16355273","title":"CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.","date":"2005","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16355273","citation_count":32,"is_preprint":false},{"pmid":"34158848","id":"PMC_34158848","title":"Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34158848","citation_count":31,"is_preprint":false},{"pmid":"7842733","id":"PMC_7842733","title":"Cloning and chromosomal localization of the human and murine genes for the T-cell transcription factors NFATc and NFATp.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7842733","citation_count":30,"is_preprint":false},{"pmid":"25152440","id":"PMC_25152440","title":"Mitf regulates osteoclastogenesis by modulating NFATc1 activity.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25152440","citation_count":30,"is_preprint":false},{"pmid":"25630465","id":"PMC_25630465","title":"NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25630465","citation_count":29,"is_preprint":false},{"pmid":"33014880","id":"PMC_33014880","title":"NFATc Acts as a Non-Canonical Phenotypic Stability Factor for a Hybrid Epithelial/Mesenchymal Phenotype.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33014880","citation_count":29,"is_preprint":false},{"pmid":"23096711","id":"PMC_23096711","title":"Lysophosphatidic acid promotes cell migration through STIM1- and Orai1-mediated Ca2+(i) mobilization and NFAT2 activation.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23096711","citation_count":28,"is_preprint":false},{"pmid":"23811942","id":"PMC_23811942","title":"Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23811942","citation_count":28,"is_preprint":false},{"pmid":"25054323","id":"PMC_25054323","title":"Arginine enhances osteoblastogenesis and inhibits adipogenesis through the regulation of Wnt and NFATc signaling in human mesenchymal stem cells.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25054323","citation_count":27,"is_preprint":false},{"pmid":"29246953","id":"PMC_29246953","title":"Ca2+-Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29246953","citation_count":27,"is_preprint":false},{"pmid":"32986812","id":"PMC_32986812","title":"Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32986812","citation_count":26,"is_preprint":false},{"pmid":"28235034","id":"PMC_28235034","title":"NFATc1 phosphorylation by DYRK1A increases its protein stability.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28235034","citation_count":26,"is_preprint":false},{"pmid":"17606988","id":"PMC_17606988","title":"Expression of the transcription factor NFAT2 in human neutrophils: IgE-dependent, Ca2+- and calcineurin-mediated NFAT2 activation.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17606988","citation_count":25,"is_preprint":false},{"pmid":"15339657","id":"PMC_15339657","title":"Sculpting heart valves with NFATc and VEGF.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15339657","citation_count":25,"is_preprint":false},{"pmid":"37020186","id":"PMC_37020186","title":"RhoA promotes osteoclastogenesis and regulates bone remodeling through mTOR-NFATc1 signaling.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37020186","citation_count":25,"is_preprint":false},{"pmid":"36137995","id":"PMC_36137995","title":"Cav2.2-NFAT2-USP43 axis promotes invadopodia formation and breast cancer metastasis through cortactin stabilization.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36137995","citation_count":24,"is_preprint":false},{"pmid":"32550905","id":"PMC_32550905","title":"Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32550905","citation_count":24,"is_preprint":false},{"pmid":"28245593","id":"PMC_28245593","title":"TNFα Increases RANKL Expression via PGE₂-Induced Activation of NFATc1.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28245593","citation_count":24,"is_preprint":false},{"pmid":"25450062","id":"PMC_25450062","title":"NFATc1 activity regulates the expression of myocilin induced by dexamethasone.","date":"2014","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/25450062","citation_count":23,"is_preprint":false},{"pmid":"26106221","id":"PMC_26106221","title":"Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners.","date":"2015","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26106221","citation_count":23,"is_preprint":false},{"pmid":"28161640","id":"PMC_28161640","title":"Gastrodin inhibits osteoclastogenesis via down-regulating the NFATc1 signaling pathway and stimulates osseointegration in vitro.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28161640","citation_count":23,"is_preprint":false},{"pmid":"24550910","id":"PMC_24550910","title":"Architecture and expression of the nfatc1 gene in lymphocytes.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24550910","citation_count":22,"is_preprint":false},{"pmid":"30828328","id":"PMC_30828328","title":"NFAT1 and NFAT2 Differentially Regulate CTL Differentiation Upon Acute Viral Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30828328","citation_count":22,"is_preprint":false},{"pmid":"31868826","id":"PMC_31868826","title":"Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox.","date":"2020","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31868826","citation_count":22,"is_preprint":false},{"pmid":"31127093","id":"PMC_31127093","title":"MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31127093","citation_count":22,"is_preprint":false},{"pmid":"32372426","id":"PMC_32372426","title":"miR-506-3p alleviates uncontrolled osteoclastogenesis via repression of RANKL/NFATc1 signaling pathway.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32372426","citation_count":21,"is_preprint":false},{"pmid":"22615493","id":"PMC_22615493","title":"Cot kinase promotes Ca2+ oscillation/calcineurin-independent osteoclastogenesis by stabilizing NFATc1 protein.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22615493","citation_count":20,"is_preprint":false},{"pmid":"37215988","id":"PMC_37215988","title":"The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37215988","citation_count":19,"is_preprint":false},{"pmid":"31319381","id":"PMC_31319381","title":"Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism.","date":"2019","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31319381","citation_count":18,"is_preprint":false},{"pmid":"31921172","id":"PMC_31921172","title":"CR3 Engaged by PGL-I Triggers Syk-Calcineurin-NFATc to Rewire the Innate Immune Response in Leprosy.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31921172","citation_count":18,"is_preprint":false},{"pmid":"31908034","id":"PMC_31908034","title":"Regulatory network mediated by RBP-J/NFATc1-miR182 controls inflammatory bone resorption.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31908034","citation_count":18,"is_preprint":false},{"pmid":"21603612","id":"PMC_21603612","title":"NFATc1 regulation of TRAIL expression in human intestinal cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21603612","citation_count":18,"is_preprint":false},{"pmid":"21384111","id":"PMC_21384111","title":"Retinoic acid inhibits NFATc1 expression and osteoclast differentiation.","date":"2011","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21384111","citation_count":17,"is_preprint":false},{"pmid":"29907883","id":"PMC_29907883","title":"B cell development is critically dependent on NFATc1 activity.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29907883","citation_count":17,"is_preprint":false},{"pmid":"38614385","id":"PMC_38614385","title":"FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38614385","citation_count":16,"is_preprint":false},{"pmid":"31362013","id":"PMC_31362013","title":"High expression of NFAT2 contributes to carboplatin resistance in lung cancer.","date":"2019","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31362013","citation_count":16,"is_preprint":false},{"pmid":"37914750","id":"PMC_37914750","title":"Essentiality of Nfatc1 short isoform in osteoclast differentiation and its self-regulation.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37914750","citation_count":16,"is_preprint":false},{"pmid":"10906142","id":"PMC_10906142","title":"Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10906142","citation_count":16,"is_preprint":false},{"pmid":"23672204","id":"PMC_23672204","title":"Regulation of de novo ceramide synthesis: the role of dihydroceramide desaturase and transcriptional factors NFATC and Hand2 in the hypoxic mouse heart.","date":"2013","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23672204","citation_count":16,"is_preprint":false},{"pmid":"25179582","id":"PMC_25179582","title":"NF-κB factors control the induction of NFATc1 in B lymphocytes.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25179582","citation_count":16,"is_preprint":false},{"pmid":"31965715","id":"PMC_31965715","title":"Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31965715","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50613,"output_tokens":12014,"usd":0.166024,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23502,"output_tokens":6103,"usd":0.135043,"stage2_stop_reason":"end_turn"},"total_usd":0.301067,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"RANKL selectively induces NFATc1 expression via TRAF6 and c-Fos signaling pathways, evokes Ca2+ oscillations leading to calcineurin-mediated NFATc1 activation, and triggers a sustained NFATc1-dependent transcriptional program during osteoclast differentiation. NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts in response to RANKL, and ectopic NFATc1 expression causes precursor cells to differentiate without RANKL, establishing NFATc1 as a master transcriptional switch downstream of RANKL for terminal osteoclast differentiation.\",\n      \"method\": \"NFATc1-deficient ES cell differentiation assay, ectopic NFATc1 expression, Ca2+ oscillation imaging, genetic epistasis (TRAF6/c-Fos pathways)\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (loss-of-function ES cells, gain-of-function ectopic expression, Ca2+ imaging, pathway genetics), widely replicated across many subsequent studies\",\n      \"pmids\": [\"12479813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Glycogen synthase kinase-3 (GSK-3) is a component of the NF-ATc kinase that phosphorylates conserved serines in the NF-ATc N-terminus, promotes nuclear export, and thereby opposes Ca2+-calcineurin signaling that drives nuclear import.\",\n      \"method\": \"Biochemical purification of NF-AT kinase, in vitro phosphorylation assay, nuclear localization assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — kinase purification plus in vitro phosphorylation assay, widely replicated and foundational finding\",\n      \"pmids\": [\"9072970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GSK-3 phosphorylation of the conserved Ser-Pro repeat motifs in NFATc negatively regulates its intrinsic DNA binding activity, in addition to controlling its subcellular localization; calcineurin-mediated dephosphorylation enhances DNA binding.\",\n      \"method\": \"Gel mobility shift assay, in vitro phosphorylation, NFATc mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation combined with mutant analysis and EMSA, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11063740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"JNK, ERK, p38, and CK2 physically associate with the NFATc N-terminal regulatory domain and directly phosphorylate Ser172 and conserved Ser-Pro repeats, blocking ionomycin-induced nuclear translocation; CK2 additionally phosphorylates a conserved motif downstream of the Ser-Pro repeats important for nuclear export.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, overexpression/inhibitor studies, subcellular localization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct in vitro phosphorylation combined with Co-IP and functional localization assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10652349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The DNA-binding domain (DBD) of NFATc has an unusual Rel-like fold that is both necessary and sufficient for DNA binding and cooperative transcriptional activation; despite overall structural homology to NF-κB p50, the two proteins use significantly different strategies for DNA recognition. A model was proposed for cooperative complex formation with AP-1 on the IL-2 enhancer.\",\n      \"method\": \"NMR solution structure determination, DNA binding assays, transcriptional activation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure with functional validation of DNA binding domain boundaries, foundational structural study\",\n      \"pmids\": [\"8990122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NFATc1 (NFATc) undergoes activity-dependent nuclear translocation in adult skeletal muscle fibers: slow-twitch electrical stimulation patterns (10 Hz continuous or 5-s trains) drive cyclosporin A-sensitive nuclear accumulation of NFATc-GFP foci, whereas fast-twitch patterns (50 Hz) or low-frequency (1 Hz) stimulation do not, indicating NFATc1 nuclear import contributes to slow fiber-type gene regulation.\",\n      \"method\": \"Live-cell GFP imaging in adult muscle fibers, electrical stimulation, pharmacological inhibition (cyclosporin A), kinase inhibitors\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct live-cell localization imaging with multiple stimulation conditions and pharmacological validation, single lab but rigorous controls\",\n      \"pmids\": [\"11581284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NFATc1 is preferentially expressed by hair follicle stem cells in their niche downstream of BMP signaling, where it transcriptionally represses CDK4 to maintain stem cell quiescence; pharmacological or genetic ablation of calcineurin/NFATc1 signaling causes premature stem cell activation and precocious follicular growth.\",\n      \"method\": \"Conditional and complete NFATc1 gene ablation, pharmacological calcineurin inhibition, reporter/ChIP assays for CDK4 repression\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with specific phenotypic readout, gene target (CDK4) identified, replicated across pharmacological and genetic approaches\",\n      \"pmids\": [\"18243104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NFATc1 binds a novel regulatory element at the pdcd1 (PD-1) locus and is required for PD-1 gene transcription upon T cell stimulation; mutation of the NFATc1 binding site abolishes promoter activity.\",\n      \"method\": \"Chromatin immunoprecipitation, reporter gene assay with binding site mutagenesis, calcineurin inhibitor and NFAT-specific inhibitor treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus mutagenesis of binding site plus reporter assay, multiple complementary methods in single lab\",\n      \"pmids\": [\"18802087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"NFATc1 isoforms B and C contain long C-terminal extensions beyond the previously described isoform A; isoform C possesses a second transactivation domain (TAD-B) in its C-terminal peptide that responds to T cell stimuli similarly to TAD-A but remains unphosphorylated, while isoform B exerts suppressive transcriptional effects through its shorter C-terminal peptide.\",\n      \"method\": \"Alternative splicing analysis, transactivation domain mapping, reporter assays, phosphorylation analysis in stimulated T cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional domain mapping with reporter assays and phosphorylation analysis, single lab\",\n      \"pmids\": [\"10358178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NFATc1 and NFATc2 are both positive regulators of IL-4 gene transcription with intrinsically similar DNA-binding and transcriptional activities at the IL-4 gene, suggesting that the disparate IL-4 phenotypes in NFAT1−/− vs. NFAT2−/− T cells arise from differential regulation of the two proteins rather than intrinsic differences in their transcriptional activities.\",\n      \"method\": \"Constitutively active NFATc mutants (alanine substitutions), IL-4 transcription assays in T cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — constitutively active mutant approach with direct transcriptional readout, single lab\",\n      \"pmids\": [\"12355451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFAT2 (NFATc1) is required in follicular regulatory T cells (TFR) to upregulate CXCR5 expression, enabling their homing to B cell follicles; T cell-specific NFAT2 ablation reduces TFR cells in follicular populations and exacerbates lupus-like autoimmune disease.\",\n      \"method\": \"T cell-specific Nfat2 conditional knockout mice, immunization experiments, flow cytometry, disease scoring\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with TFR-intrinsic rescue experiments and mechanistic link to CXCR5 upregulation, multiple phenotypic readouts\",\n      \"pmids\": [\"24590764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NFATc1 is required cell-intrinsically for normal B-1a cell development; NFATc1-deficient mice lack peritoneal and splenic B-1a cells, while NFATc2-deficient mice have a normal B-1a compartment; NFATc1 protein is elevated ~5-fold in B-1a versus B-2 cells.\",\n      \"method\": \"NFATc1-deficient and NFATc2-deficient mouse analysis, mixed-allotype chimeras, retroviral gene transduction, flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation plus cell-intrinsic rescue by retroviral transduction, multiple complementary approaches\",\n      \"pmids\": [\"14595020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The calcineurin-NFATc pathway directly regulates AQP2 (aquaporin-2) expression in renal collecting duct cells through functional NFAT binding sites in the AQP2 proximal promoter; hypertonicity promotes nuclear translocation of NFATc proteins (in addition to TonEBP/NFAT5) to induce AQP2, and calcineurin activity is involved in TonEBP/NFAT5 induction by hypertonicity.\",\n      \"method\": \"Promoter mutational analysis, chromatin immunoprecipitation, nuclear translocation assays, calcineurin inhibitor studies\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus promoter mutagenesis plus nuclear translocation assays, multiple orthogonal methods in single study\",\n      \"pmids\": [\"17166937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NFATC1 is expressed in epicardium-derived cells and is required for their invasion into myocardium; RANKL/calcineurin signaling activates NFATC1 to induce cathepsin K (CTSK) expression, enabling ECM degradation and cell invasion; loss of NFATC1 in EPDCs causes reduced coronary vessel and fibrous matrix penetration and embryonic lethality by E18.5.\",\n      \"method\": \"Conditional NFATC1 knockout in EPDCs, RANKL treatment of PE-derived cell cultures, in vivo CTSK expression analysis, calcineurin inhibitor experiments\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific phenotype, target gene (CTSK) identified, pharmacological and genetic validation, multiple approaches\",\n      \"pmids\": [\"21447555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NFATc1 is required for lymphatic endothelial development; in NFATc1-null mice, lymphatic endothelial cells fail to properly coalesce into lymph sacs; calcineurin inhibition with cyclosporin A reduces podoplanin and FGFR-3 expression in lymphatics; NFATc1 siRNA reduces VEGFR-3 and podoplanin expression and NFATc1 activates lymphatic-specific gene promoters.\",\n      \"method\": \"NFATc1 knockout mouse analysis, cyclosporin A treatment in utero, siRNA knockdown, reporter assays, immunofluorescence co-localization\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic ablation plus pharmacological inhibition plus siRNA plus reporter assays, multiple orthogonal approaches\",\n      \"pmids\": [\"19233265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cartilage-specific ablation of NFATc1 in NFATc2-deficient mice leads to early onset aggressive osteoarthritis with loss of proteoglycans, collagen/aggrecan degradation, osteophyte formation, and joint instability, indicating NFATc1 and NFATc2 cooperate to repress spontaneous OA in chondrocytes.\",\n      \"method\": \"Cartilage-specific NFATc1 conditional knockout in NFATc2-/- mice, histomorphometry, micro-CT, analysis of human OA cartilage samples\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double genetic ablation with specific phenotype, histological and structural phenotyping, corroborated by human tissue data\",\n      \"pmids\": [\"24248346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IKKε phosphorylates NFATc1 during T cell activation, promoting its cytoplasmic retention and inhibiting T cell antitumor and antiviral immune responses; loss of IKKε elevates T cell immunity, while constitutively nuclear NFATc1 restores sorafenib resistance in IKKε-activated contexts.\",\n      \"method\": \"Kinase assay, T cell activation assays, IKKε knockout mice, tumor and viral infection models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct kinase assay for phosphorylation plus in vivo genetic knockout, single lab\",\n      \"pmids\": [\"27346349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NFATc1 controls cytotoxic T lymphocyte effector functions including cytoskeleton organization, recruitment of cytosolic organelles to immunological synapses, and glycolytic metabolic switching; NFATc1-deficient CD8+ T cells show impaired cytotoxicity and glycolysis that can be restored by IL-2. Genome-wide ChIP-seq confirms NFATc1 binding to genes controlling CTL activity including Tbx21 and Gzmb.\",\n      \"method\": \"Nfatc1 conditional KO in T cells, genome-wide ChIP-seq, transcriptome analysis, metabolic assays, in vivo infection/tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined cellular and metabolic phenotypes plus ChIP-seq, multiple orthogonal methods\",\n      \"pmids\": [\"28894104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DYRK1A phosphorylates NFATc1/αA at S261, S278, S403, and S409, which interferes with NFATc1 ubiquitination and proteasomal degradation, thereby stabilizing the protein and increasing its transcriptional activity—contrary to its suppressive role on NFATc2.\",\n      \"method\": \"In vitro kinase assay with site-specific mutagenesis, ubiquitination assay, protein stability assay, transcriptional reporter assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis plus ubiquitination assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"28235034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SUMOylation of NFATc1 represses IL-2 production in T cells in vivo; transgenic mice in which NFATc1 SUMOylation is prevented show elevated IL-2, expanded regulatory T cells, and ameliorated autoimmune encephalomyelitis and graft-versus-host disease. Mechanistically, increased IL-2 counteracts IL-17/IFN-γ through STAT5 and Blimp-1 induction.\",\n      \"method\": \"SUMO-site mutant transgenic mouse generation, in vivo EAE and GVHD models, cytokine and transcription factor analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic mouse with defined SUMO-site mutation, multiple in vivo disease models, mechanistic pathway dissection\",\n      \"pmids\": [\"32986812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT3 drives NFATc1 transcription by directly binding to the NFATc1 promoter in osteoclast precursors; conditional deletion of Stat3 in osteoclasts reduces NFATc1 expression and impairs osteoclast differentiation, and enforced NFATc1 expression rescues the Stat3-deficient differentiation defect.\",\n      \"method\": \"Osteoclast-specific Stat3 conditional knockout (Ctsk-Cre), promoter binding by ChIP, NFATc1 rescue experiments, STAT3 inhibitor (AG490)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus ChIP plus rescue experiment, multiple orthogonal approaches, epistasis established\",\n      \"pmids\": [\"31462535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc1 directly binds the Itpr2 promoter and regulates InsP3R2 (type 2 IP3 receptor) gene expression in cardiomyocytes; calcineurin-NFATc1 signaling upregulates InsP3R2 in cardiac hypertrophy, forming a positive feedback loop because InsP3R2-mediated Ca2+ release activates calcineurin-NFATc.\",\n      \"method\": \"Promoter-reporter assay, chromatin immunoprecipitation, calcineurin transgenic mice, calcineurin inhibitor studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding by ChIP plus functional reporter plus transgenic mouse model, multiple orthogonal methods\",\n      \"pmids\": [\"24415751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FOXP3 competes with NFAT1 for binding to the endogenous NFAT2 (NFATc1) promoter, suppressing NFAT2 transcription in regulatory T cells; ectopic NFAT2 expression in FOXP3+ Treg cells partially restores IL-2 production, indicating FOXP3-mediated NFAT2 repression contributes to the anergic phenotype.\",\n      \"method\": \"Chromatin immunoprecipitation, inducible FOXP3 expression, retroviral NFAT2 overexpression, promoter reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing competitive promoter occupancy plus functional rescue by ectopic NFAT2, multiple orthogonal methods\",\n      \"pmids\": [\"19564342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NF-κB1/p50 and c-Rel control the induction of NFATc1/αA in BCR-stimulated B cells via two composite κB/NFAT-binding sites in the inducible Nfatc1 P1 promoter.\",\n      \"method\": \"B cell-specific NF-κB knockouts, promoter-reporter assays with binding site analysis, BCR stimulation experiments\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockouts plus promoter reporter with binding site analysis, single lab\",\n      \"pmids\": [\"25179582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Transient activation of the serine synthesis pathway (SSP) is required for osteoclastogenesis; SSP-derived α-ketoglutarate is necessary for histone demethylases that remove repressive histone methylation marks at the Nfatc1 gene locus, thereby inducing NFATc1 expression and osteoclast maturation. Deletion of the rate-limiting SSP enzyme phosphoglycerate dehydrogenase in osteoclast progenitors impairs differentiation.\",\n      \"method\": \"Osteoclast progenitor-specific PHGDH deletion, chromatin/histone methylation analysis, metabolite supplementation, OVX mouse model\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus epigenetic mechanistic dissection plus metabolite rescue, multiple orthogonal methods establishing metabolic-epigenetic coupling\",\n      \"pmids\": [\"38200114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NFATc1 transcriptionally upregulates SLC7A11 (xCT) during RANKL-induced osteoclastogenesis, increasing cystine import in osteoclast precursors; during TXNRD1 inhibition this causes cystine accumulation and disulfidptosis, selectively killing osteoclast precursors over BMDMs.\",\n      \"method\": \"NFATc1 ChIP/transcriptional assay for SLC7A11 promoter, TXNRD1 inhibitor treatment, rescue with SLC7A11 inhibitors, OVX mouse model\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP/transcriptional regulation plus pharmacological rescue experiments, single lab\",\n      \"pmids\": [\"37148740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cot (Tpl-2) serine/threonine kinase directly phosphorylates NFATc1 (and all other NFATc family members) and increases NFATc1 protein stability, promoting Ca2+ oscillation/calcineurin-independent osteoclastogenesis through osteoblast-osteoclast cell-cell contact.\",\n      \"method\": \"In vitro kinase assay, co-culture system, Cot overexpression/knockdown, NFATc1 stability assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay plus protein stability assay plus cell-based functional validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22615493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCR1 is a direct transcriptional target of NFATc1/NFAT2 during RANKL-induced osteoclastogenesis; the CCR1 upstream regulatory region shows RANKL-dependent, cyclosporin A-suppressible promoter activity; CCR1 signaling downstream of NFAT2 enhances migration of differentiating osteoclasts.\",\n      \"method\": \"Microarray analysis, quantitative RT-PCR, luciferase promoter reporter assay, CCR1 siRNA, Boyden chamber migration assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter with pharmacological validation plus siRNA functional assay, single lab\",\n      \"pmids\": [\"16355273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NFATc (NFATc4 expressed in tendons) binds TSE1 in nuclear extracts from tendon fibroblasts and transactivates the COL1a1 promoter through this element; inhibition of NFATc nuclear translocation strongly inhibits COL1a1 gene expression, suggesting NFATc and scleraxis cooperate to activate type I collagen expression specifically in tendon fibroblasts.\",\n      \"method\": \"Gel shift assay (EMSA), transfection/reporter assays, pharmacological NFATc nuclear translocation inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus reporter assay plus functional inhibition, single lab, note this study focuses on NFATc4 not NFATc1 specifically\",\n      \"pmids\": [\"17430895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NFATc1 is required for TGF-β-mediated transcriptional induction of fibronectin in mesangial cells; constitutively active calcineurin increases fibronectin transcription, and dominant-negative NFATc or NFATc1 inhibition blocks TGF-β-mediated fibronectin promoter activation.\",\n      \"method\": \"Calcineurin inhibitors, constitutively active calcineurin overexpression, dominant-negative NFATc expression, promoter reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss of function approaches with promoter reporter, single lab\",\n      \"pmids\": [\"17719012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"High glucose activates NFATc1 (NFAT2) in podocytes via increased intracellular Ca2+ leading to calcineurin activation, and NFATc1 mediates podocyte apoptosis through transcriptional upregulation of Bax; calcineurin/NFAT2 inhibition blocks both nuclear accumulation and apoptosis.\",\n      \"method\": \"Immunofluorescence, western blot, flow cytometry, Ca2+ imaging with Fluo-3/AM, calcineurin inhibitors, NFAT2-specific inhibitor (11R-VIVIT)\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple complementary methods establishing Ca2+/calcineurin/NFATc1/Bax pathway, single lab\",\n      \"pmids\": [\"23340267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The calcineurin/NFATc1 signaling pathway promotes HCC cell proliferation; calcineurin-regulated NFATc1 nuclear import/export is demonstrated in HepG2 cells, and NFATc1 knockdown causes G1 cell cycle arrest and reduces c-Myc and COX-2 expression, suggesting NFATc1 drives proliferation through these oncogenes.\",\n      \"method\": \"NFATc1 siRNA knockdown, immunofluorescence, western blot, flow cytometry cell cycle analysis, ionomycin/cyclosporin A treatment\",\n      \"journal\": \"Digestive diseases and sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with downstream target analysis, multiple assays, single lab\",\n      \"pmids\": [\"22722879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NFATc1 drives EMT reprogramming and maintains pancreatic cancer cells in a stem cell-like state through Sox2-dependent transcription of EMT and stemness factors; NFATc1-Sox2 complex-mediated dedifferentiation is opposed by p53-miR200c signaling, and inactivation of the p53 pathway is required for NFATc1-driven tumor dedifferentiation.\",\n      \"method\": \"NFATc1 gain/loss of function, Sox2 co-expression analysis, genetically engineered mouse models, transcriptional reporter assays, human PDAC analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional experiments in cell lines and GEMM with mechanistic link to Sox2, single lab\",\n      \"pmids\": [\"25586376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The deubiquitinase UCHL1 deubiquitinates and stabilizes TAZ at K46 by removing K48-linked polyubiquitination; stabilized TAZ inhibits NFATc1 dephosphorylation and nuclear transport by competing with calcineurin A for binding to NFATc1, thereby negatively regulating osteoclastogenesis.\",\n      \"method\": \"Osteoclast-specific UCHL1 conditional KO, proteomic analysis, ubiquitination assay, Co-IP (TAZ-calcineurin-NFATc1 competition), OVX mouse model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO plus Co-IP competition assay plus ubiquitination biochemistry, single lab\",\n      \"pmids\": [\"37215988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Zebrafish Nfatc1 is required for valve interstitial cell (VIC) formation in cardiac valve development by promoting proliferation and endocardial/neural crest cell recruitment; Nfatc1 promotes expression of twist1b (a regulator of endothelial-to-mesenchymal transition) as a downstream effector; loss of Nfatc1 results in valvular dysfunction with persistent retrograde blood flow.\",\n      \"method\": \"Zebrafish nfatc1 mutants, live imaging, high-speed microscopy, echocardiography, transcriptional target analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with live imaging, downstream effector identified, single lab\",\n      \"pmids\": [\"32070236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NFAT2 (NFATc1) is a critical regulator of the anergic phenotype in CLL B cells; B cell-specific ablation of Nfat2 leads to loss of anergy and transformation to aggressive disease; NFAT2-dependent gene expression signature includes Cbl-b, Grail, Egr2, and Lck.\",\n      \"method\": \"B cell-specific Nfat2 conditional knockout mouse CLL models, gene expression analysis, human CLL biopsy analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in disease model with defined gene signature and human corroboration, multiple approaches\",\n      \"pmids\": [\"28970470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc1 activity is required for early B cell development; loss of NFATc1 in pro-B cells suppresses EBF1 expression, impairs immunoglobulin gene rearrangement and preBCR formation, arresting pro-B to pre-B cell transition and causing severe B cell lymphopenia.\",\n      \"method\": \"Multiple NFATc1-deficient mouse models, bone marrow analysis, flow cytometry, immunoglobulin rearrangement assays\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic mouse models with specific molecular mechanism (EBF1 suppression, Ig rearrangement impairment) identified\",\n      \"pmids\": [\"29907883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NFATc1 drives NAFLD progression through chronic ER stress sensing and activation of the PERK-CHOP unfolded protein response pathway in hepatocytes; hepatocyte-specific NFATc1 depletion prevents disease acceleration in high-fat western diet-fed mice, and NFATc1-induced NASH progression can be blocked by TUDCA.\",\n      \"method\": \"Hepatocyte-specific NFATc1 transgenic/KO mice, western diet feeding, UPR pathway analysis, TUDCA treatment, human NAFLD patient samples\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO and overexpression plus mechanistic UPR pathway analysis plus pharmacological rescue, human tissue corroboration\",\n      \"pmids\": [\"35365570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NFATc1 regulates dexamethasone-induced myocilin (MYOC) expression in human trabecular meshwork cells via calcineurin activation; dexamethasone causes calcium-independent NFATc1 nuclear translocation within 15 minutes, and both calcineurin inhibitors and NFATc1 siRNA block DEX-induced MYOC mRNA increase.\",\n      \"method\": \"Calcineurin inhibitors (cyclosporin A, INCA-6), NFATc1 siRNA, immunofluorescence nuclear translocation assay, qRT-PCR\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown plus pharmacological inhibition plus nuclear translocation assay, single lab\",\n      \"pmids\": [\"25450062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NFATc1 regulates TRAIL expression in intestinal cells by activating the TRAIL promoter and negatively regulating Sp1 binding to the TRAIL promoter; knockdown of NFATc1 increases Sp1 binding and inhibition of Sp1 increases TRAIL expression, indicating an indirect regulatory mechanism.\",\n      \"method\": \"NFATc1 knockdown, Sp1 inhibition, promoter activity assay, chromatin analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus Sp1 binding analysis plus dual knockdown approach, single lab\",\n      \"pmids\": [\"21603612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-2 and IL-15 oppositely regulate CX3CR1 expression through differential recruitment of NFAT2 versus NFAT1 to a κB-like NFAT site in the CX3CR1 promoter; IL-2 promotes NFAT2 binding while IL-15 promotes NFAT1 binding, as demonstrated by ChIP.\",\n      \"method\": \"Chromatin immunoprecipitation, NFAT1-/- mice, promoter mutation assays, luciferase reporter in PBMCs, NFAT inhibitor experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for differential promoter occupancy plus genetic mouse model plus promoter mutation plus pharmacological inhibition, multiple orthogonal approaches\",\n      \"pmids\": [\"15347678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CR3 engagement by M. leprae PGL-I activates the Syk tyrosine kinase, which induces calcineurin-dependent nuclear translocation of NFATc in innate immune cells (macrophages, neutrophils, dendritic cells), selectively augmenting production of IL-2 (DCs), IL-10 (PMNs), and IL-1β (macrophages).\",\n      \"method\": \"CR3 engagement assays, Syk inhibition, calcineurin inhibition, NFATc nuclear translocation imaging, cytokine measurements, intranasal infection model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with in vivo infection model, single lab\",\n      \"pmids\": [\"31921172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NFATc1-mediated calcineurin signaling activation in mesangial cells drives uPAR-ITGB3 pathway activation; calcineurin-NFATC inhibition by miR-30 family blocks this pathway. In cultured podocytes, calcineurin-NFATC signaling activates the uPAR-ITGB3 pathway, leading to Rho GTPase activation, synaptopodin downregulation, and cytoskeletal injury.\",\n      \"method\": \"Podocyte-specific miR-30 KO, calcineurin/NFATC inhibitors, Transwell co-culture system, podocyte-specific transgenic miR-30, cytoskeletal assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO plus pharmacological inhibition plus transgenic rescue, single lab\",\n      \"pmids\": [\"31127093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"KCa3.1 (a Ca2+-activated K+ channel) modulates Ca2+-induced NFATc1 activation during inflammatory osteoclastogenesis via the CaMKIV/CREB/c-Fos axis; KCa3.1 deficiency or TRAM-34 blockade reduces RANKL-induced Ca2+ transient amplitudes by ~50% and decreases NFATc1 expression and transcriptional activity.\",\n      \"method\": \"KCa3.1 knockout mice, TRAM-34 pharmacological inhibition, live cell Ca2+ imaging, western blot for pathway components, BMM culture osteoclastogenesis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus live Ca2+ imaging plus pathway western blots, single lab\",\n      \"pmids\": [\"29246953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The short NFATc1/αA isoform is essential for osteoclastogenesis and self-regulation; NFATc1/αA-specific knockout mice die in utero by E13.5, and in a novel hematopoietic stem cell differentiation culture system, loss of NFATc1/αA impairs osteoclast differentiation and expression of osteoclast markers and Nfatc1 regulators.\",\n      \"method\": \"Short-isoform-specific NFATc1/αA knockout mouse, novel HSC-to-osteoclast in vitro culture system, gene expression analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific genetic KO with functional differentiation assay, single lab\",\n      \"pmids\": [\"37914750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Homer2 and Homer3 regulate NFATc1 function in osteoclastogenesis by interacting with NFATc1 and competing with its activation by calcineurin; RANKL treatment inhibits Homer-NFATc1 interaction, which is restored by calcineurin inhibition (cyclosporin A). Homer2/3 double knockout markedly decreases bone density.\",\n      \"method\": \"Homer2/3 double knockout mice, BMM osteoclastogenesis assay, Co-IP of Homer-NFATc1, calcineurin inhibitor experiments, micro-CT\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus Co-IP demonstrating physical interaction, single lab\",\n      \"pmids\": [\"31319381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GATA5 and NF-ATc (NFATc1) synergistically activate endocardial transcription; inhibition of either GATA5 expression or NF-ATc activation blocks terminal endothelial-endocardial differentiation at a pre-endocardial stage in an in vitro model of cardiogenic differentiation.\",\n      \"method\": \"In vitro cardiogenic differentiation model, calcineurin/NF-ATc inhibition, GATA5 expression manipulation, transcriptional reporter assays\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro differentiation model with loss-of-function for both factors plus synergy reporter assays, single lab\",\n      \"pmids\": [\"12163407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NFATc1 (NFAT2) suppresses E-cadherin expression by transcriptionally upregulating Snail and Zeb1 in a TGF-β-independent manner, promoting cancer cell invasion; inducible constitutively active NFATc1 expression promotes invasion in A549 and MCF7 cells and in tumor xenografts in vivo.\",\n      \"method\": \"Inducible constitutively active NFATc1 expression, RNA interference, cell invasion assay, tumor xenograft, gene expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible expression with identified downstream targets plus in vivo xenograft validation, single lab\",\n      \"pmids\": [\"23811942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NFAT2 regulates HDAC1 transcriptional activity in glioblastoma stem cells; NFAT2-HDAC1 signaling maintains the mesenchymal phenotype, and loss of both NFAT2 and HDAC1 causes hyperacetylation of NF-κB, inhibiting NF-κB-dependent transcription.\",\n      \"method\": \"NFAT2 siRNA knockdown, HDAC1 rescue experiments, NFAT2 overexpression, NF-κB acetylation analysis, in vivo tumorigenicity\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown plus rescue plus downstream pathway analysis, single lab\",\n      \"pmids\": [\"31400279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RBP-J represses while NFATc1 activates miR182 expression in TNF-induced osteoclastogenesis through binding to specific open chromatin regions in the miR182 promoter; this RBP-J/NFATc1-miR182 regulatory network controls the balance between activating and repressive signals in inflammatory osteoclastogenesis.\",\n      \"method\": \"ChIP for NFATc1 and RBP-J binding to miR182 promoter, miR182 inhibition, open chromatin analysis, in vivo inflammatory arthritis model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for promoter binding plus functional miRNA experiments, single lab\",\n      \"pmids\": [\"31908034\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFATc1 is a Ca2+/calcineurin-regulated transcription factor that, upon dephosphorylation by calcineurin at conserved Ser-Pro repeat motifs, translocates to the nucleus where it acts as a master transcriptional regulator of osteoclast differentiation (downstream of RANKL-TRAF6-c-Fos) and controls diverse processes including T and B lymphocyte activation and differentiation, hair follicle stem cell quiescence (via CDK4 repression), cardiac valve and lymphatic development, and glycolytic/metabolic reprogramming; its activity is negatively regulated by multiple kinases (GSK-3, JNK, ERK, p38, CK2, IKKε, DYRK1A) that phosphorylate it to drive nuclear export or proteasomal degradation, and by post-translational SUMOylation that represses IL-2 production, while Cot kinase and DYRK1A can stabilize NFATc1 protein through phosphorylation-mediated interference with ubiquitination.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NFATc1 is a Ca2+/calcineurin-regulated transcription factor whose DNA-binding domain adopts a Rel-like fold that recognizes target promoters and cooperates with partner factors such as AP-1 on composite elements [#4]. Its activity is gated by phosphorylation: GSK-3, JNK, ERK, p38, CK2, and IKKε associate with and phosphorylate conserved Ser-Pro repeat motifs and Ser172 in the N-terminal regulatory domain, opposing calcineurin-mediated dephosphorylation by promoting cytoplasmic retention/nuclear export and reducing intrinsic DNA binding, while calcineurin dephosphorylation drives nuclear import and enhances DNA binding [#1, #2, #3, #16]. Protein abundance is further tuned by phosphorylation-dependent stabilization through Cot/Tpl-2 and DYRK1A (which block ubiquitination) and by SUMOylation that represses IL-2 output [#18, #19, #26]. The best-defined biological role of NFATc1 is as the master transcriptional switch for terminal osteoclast differentiation downstream of RANKL-TRAF6-c-Fos and Ca2+/calcineurin signaling [#0]; its induction at the Nfatc1 locus depends on STAT3 and on serine-synthesis-derived α-ketoglutarate that feeds histone demethylases to remove repressive marks, and it drives an osteoclastogenic gene program including CCR1, SLC7A11, and miR182 [#20, #24, #25, #27, #49]. Beyond bone, NFATc1 governs lymphocyte development and function—B-1a cell development, pro-B to pre-B transition via EBF1, cytotoxic T cell effector functions and glycolytic reprogramming, follicular regulatory T cell homing via CXCR5, and anergy programs—and it controls cardiac valve, lymphatic, and epicardial development, hair follicle stem cell quiescence through CDK4 repression, and disease-associated transcriptional programs in cancer and metabolic/fibrotic tissues [#6, #10, #11, #14, #17, #34, #35, #36, #37].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established how NFATc activity is negatively controlled, identifying GSK-3 as a kinase that phosphorylates the conserved N-terminal serines to drive nuclear export and oppose Ca2+-calcineurin import.\",\n      \"evidence\": \"Biochemical purification of NF-AT kinase and in vitro phosphorylation with nuclear localization assays\",\n      \"pmids\": [\"9072970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map all physiological GSK-3 priming events\", \"In vivo relevance to specific tissues not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined the structural basis of NFATc DNA recognition, showing a Rel-like DBD necessary and sufficient for binding and cooperative activation distinct from NF-κB p50.\",\n      \"evidence\": \"NMR solution structure with DNA binding and transcriptional activation assays\",\n      \"pmids\": [\"8990122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full-length protein or partner co-complexes\", \"AP-1 cooperativity modeled but not crystallographically resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended kinase regulation by showing GSK-3 and MAPKs/CK2 phosphorylation controls not only localization but also intrinsic DNA binding, and that multiple kinases physically dock on the N-terminal domain to block nuclear translocation.\",\n      \"evidence\": \"EMSA, in vitro kinase assays, Co-IP, mutant analysis, and subcellular localization assays\",\n      \"pmids\": [\"11063740\", \"10652349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and ordering of multi-kinase phosphorylation unresolved\", \"Phosphatase counteraction kinetics not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed NFATc1 isoform diversity generates distinct transactivation capacities, with isoform C containing a second TAD and isoform B exerting suppression.\",\n      \"evidence\": \"Alternative splicing analysis, TAD mapping, reporter and phosphorylation assays in T cells\",\n      \"pmids\": [\"10358178\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab characterization\", \"Tissue-specific isoform usage not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified NFATc1 as the master transcriptional switch for terminal osteoclast differentiation downstream of RANKL-TRAF6-c-Fos and Ca2+/calcineurin signaling.\",\n      \"evidence\": \"NFATc1-deficient ES cell differentiation, ectopic expression, Ca2+ imaging, pathway genetics\",\n      \"pmids\": [\"12479813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full downstream target program not enumerated at the time\", \"Mechanism of sustained autoamplification not detailed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Clarified that disparate NFATc1 vs NFATc2 cytokine phenotypes arise from differential regulation rather than intrinsic transcriptional differences at IL-4.\",\n      \"evidence\": \"Constitutively active alanine-substitution mutants with IL-4 transcription assays in T cells\",\n      \"pmids\": [\"12355451\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single transcriptional readout\", \"Differential upstream regulation not directly dissected\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated NFATc1 cooperates with GATA5 to drive endocardial differentiation, linking it to early cardiac development.\",\n      \"evidence\": \"In vitro cardiogenic differentiation with loss-of-function and synergy reporter assays\",\n      \"pmids\": [\"12163407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro model only\", \"Direct target genes not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a repressive transcriptional role in stem cell maintenance, with NFATc1 repressing CDK4 to keep hair follicle stem cells quiescent downstream of BMP.\",\n      \"evidence\": \"Conditional and complete gene ablation, calcineurin inhibition, reporter/ChIP for CDK4\",\n      \"pmids\": [\"18243104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor machinery at CDK4 not defined\", \"Generalizability to other stem cell niches untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established a cell-intrinsic, NFATc1-specific (vs NFATc2) requirement for B-1a cell development.\",\n      \"evidence\": \"NFATc1- and NFATc2-deficient mice, mixed chimeras, retroviral rescue, flow cytometry\",\n      \"pmids\": [\"14595020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct B-1a target genes not identified\", \"Isoform responsible not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined cross-regulation among NFAT family members and FOXP3, showing FOXP3 competes with NFAT1 at the NFATc1 promoter to enforce Treg anergy, and IL-2/IL-15 differentially recruit NFAT2 vs NFAT1 to target promoters.\",\n      \"evidence\": \"ChIP, inducible FOXP3 expression, retroviral rescue, promoter mutation, NFAT1-/- mice\",\n      \"pmids\": [\"19564342\", \"15347678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of family-member-selective recruitment unresolved\", \"In vivo competition dynamics not quantified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended NFATc1 to developmental ECM remodeling, showing RANKL/calcineurin-NFATC1 induces cathepsin K to enable epicardium-derived cell invasion.\",\n      \"evidence\": \"Conditional EPDC knockout, RANKL treatment, in vivo CTSK analysis, calcineurin inhibition\",\n      \"pmids\": [\"21447555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CTSK promoter occupancy not shown\", \"Other invasion effectors not enumerated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established a requirement for NFATc1 in lymphatic endothelial coalescence and lymphatic gene expression.\",\n      \"evidence\": \"Knockout mice, in utero cyclosporin A, siRNA, reporter assays, immunofluorescence\",\n      \"pmids\": [\"19233265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect regulation of VEGFR-3/podoplanin not separated\", \"Upstream activator in lymphatics unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected calcineurin-NFATc1 signaling to disease-driving transcriptional programs across multiple tissues including cardiac hypertrophy feedback (Itpr2), chondroprotection, podocyte apoptosis (Bax), and cancer invasion.\",\n      \"evidence\": \"ChIP/promoter assays, transgenic and conditional KO mice, inducible constitutively active NFATc1, invasion and apoptosis assays\",\n      \"pmids\": [\"24415751\", \"24248346\", \"23340267\", \"23811942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-specific cofactors driving opposite (activating vs repressive) outputs unresolved\", \"Several cancer findings are single-lab Medium-confidence\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped upstream transcriptional induction of NFATc1 itself in B cells (NF-κB1/p50 and c-Rel at the P1 promoter) and defined its role in early B cell development via EBF1 and immunoglobulin rearrangement.\",\n      \"evidence\": \"B cell-specific NF-κB and NFATc1 knockouts, promoter-reporter binding-site analysis, Ig rearrangement assays\",\n      \"pmids\": [\"25179582\", \"29907883\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct EBF1 promoter occupancy by NFATc1 not shown\", \"Isoform-specific contributions not separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined NFATc1 control of follicular regulatory T cell positioning via CXCR5 upregulation, with autoimmune consequences.\",\n      \"evidence\": \"T cell-specific Nfat2 conditional knockout, immunization, flow cytometry, disease scoring\",\n      \"pmids\": [\"24590764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Cxcr5 promoter binding not demonstrated\", \"Cofactor requirements in TFR cells unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified IKKε as an additional negative regulatory kinase retaining NFATc1 in the cytoplasm to dampen T cell antitumor/antiviral immunity.\",\n      \"evidence\": \"Kinase assay, T cell activation assays, IKKε knockout mice, tumor/viral models\",\n      \"pmids\": [\"27346349\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite mapping incomplete\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed NFATc1 directly programs cytotoxic T cell effector function, synapse organization, and glycolytic metabolic switching, with genome-wide target identification including Tbx21 and Gzmb.\",\n      \"evidence\": \"Conditional T cell KO, ChIP-seq, transcriptomics, metabolic assays, in vivo models\",\n      \"pmids\": [\"28894104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect metabolic gene targets not fully separated\", \"IL-2 rescue mechanism not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved a paradoxical positive post-translational regulation: DYRK1A phosphorylation at specific serines blocks NFATc1 ubiquitination and stabilizes it, opposite to its effect on NFATc2.\",\n      \"evidence\": \"In vitro kinase assay with site mutagenesis, ubiquitination assay, stability and reporter assays\",\n      \"pmids\": [\"28235034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase blocked by phosphorylation not identified\", \"In vivo relevance limited\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established STAT3 as a direct transcriptional activator of the Nfatc1 gene in osteoclast precursors, placing NFATc1 induction within a defined upstream cascade.\",\n      \"evidence\": \"Osteoclast-specific Stat3 conditional KO, ChIP, NFATc1 rescue, STAT3 inhibitor\",\n      \"pmids\": [\"31462535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with calcineurin-driven autoamplification not dissected\", \"Other STAT3 cofactors at the locus unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated SUMOylation as a physiological brake on NFATc1, repressing IL-2 to limit Treg expansion and autoimmunity in vivo.\",\n      \"evidence\": \"SUMO-site mutant transgenic mice, EAE and GVHD models, cytokine/TF analysis\",\n      \"pmids\": [\"32986812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO E3 ligase and target lysines mechanistic detail limited\", \"Tissue-specificity of SUMO regulation not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Uncovered additional layers of stability control and metabolic gene coupling, including UCHL1-TAZ competition with calcineurin for NFATc1 and NFATc1-driven SLC7A11 import linking osteoclast precursors to disulfidptosis.\",\n      \"evidence\": \"Conditional KOs, Co-IP competition, ubiquitination biochemistry, ChIP, pharmacological rescue, OVX models\",\n      \"pmids\": [\"37215988\", \"37148740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings\", \"Direct structural basis of TAZ-calcineurin competition for NFATc1 not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked metabolism to NFATc1 induction epigenetically, showing serine-synthesis-derived α-ketoglutarate is required for histone demethylation at the Nfatc1 locus during osteoclastogenesis.\",\n      \"evidence\": \"Osteoclast progenitor PHGDH deletion, histone methylation analysis, metabolite rescue, OVX model\",\n      \"pmids\": [\"38200114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific demethylases acting at the locus not definitively assigned\", \"Generalizability beyond osteoclasts untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How tissue- and context-specific cofactors switch NFATc1 between transcriptional activation and repression of overlapping target sets, and how the full network of stabilizing vs destabilizing post-translational modifications is integrated in vivo, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of activator-vs-repressor output selection\", \"E3 ligases and SUMO machinery acting on NFATc1 incompletely defined\", \"Isoform-specific functional division of labor not comprehensively mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 7, 17, 32, 35, 47]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 4, 7, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 5, 31]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 3, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 7, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 17, 35, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 14, 34, 46]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 24, 37]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PPP3CA\", \"GSK3B\", \"DYRK1A\", \"FOXP3\", \"SOX2\", \"HOMER2\", \"HOMER3\", \"TAZ\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}